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Abstract: 
The purpose of this thesis is to investigate the effects of anabolic-androgenic steroids 
on aging in bodybuilders, because they are thought to be the people with the most intensive 
steroid abuse. This thesis is motivated by the following concept: when a cell divides its 
telomeres shorten, and after a certain number of divisions, the cell dies (1-4). This 
observation leads into a connection between telomere shortening, and aging in humans. 
Therefore, I propose this hypothesis: if steroids increase cell division, then the people 
taking steroids regularly will die sooner, because their telomeres will shorten faster. I will 
look at data showing average telomere shrinkage, causes and age of death of people that have 
never used anabolic steroids and then compare that to bodybuilders and other athletes that are 
known to have taken these drugs on regular bases. 
In contrast, if steroids cause an increase in cell size instead, then we might expect a 
relationship between cell size and apoptosis (cell death). In this scenario, people abusing 
anabolic substances would experience an increase in their cells' size possibly causing 
apoptosis, which, again, would eventually lead to an earlier death. 
There is another possible scenario, which involves muscle cells with multiple nuclei. 
If nuclear multiplication were induced by steroids as muscle cell size increases, telomeres 
would again shorten prematurely. An alternate possibility, of why steroid abusers suffer 
from early death, might be the already commonly known side effects of the anabolic-
androgenic steroids that are not related to cell aging. 
I will be investigating these phenomena together with other relevant facts that 
emerge. Another very important thing that I need to consider is the probability that steroids 
do not contribute significantly to muscular growth, and strength in bodybuilders. Steroids 
might only be causing the body to retain salt and water making the muscle tissue bigger. The 
purpose is to consolidate disparate knowledge on this subject. 
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Introduction: 
Cellular Aging and Telomeres 
Programmed cell death is a critical element in normal growth and development. In 
adult mammals, the majority of cells are mortal, meaning that they will live for a given 
number of divisions and then enter a cell death pathway. The Hayflick limit hypothesis 
states that the number of fibroblast doublings in culture varies roughly in accordance with 
lifespan of the source animal (5-15). Hayflick observed this phenomenon for many cells in 
culture. Recently, a molecular mechanism involving telomeres, the ends of chromosomes, 
has been proposed to explain one method by which cells monitor their age. 
As alluded to above, telomeres are chromatin domains at the ends of eukaryotic 
chromosomes that protect chromosomes from degradation and from end-to-end fusion (16, 
17). In most organisms, telomeric DNA is composed of simple tandem repeats in which one 
strand is G-rich and runs 5' to 3' towards the end of the chromosome (18). This G-rich strand 
extends as a single-stranded 3' overhang of about two repeats (19-21). 
Conventional DNA polymerases cannot replicate a 3' overhang, so, in the absence of a 
repair mechanism, a chromosome is expected to get shorter with each round of DNA 
replication (22). Telomerase is a ribonucleoprotein (RNP) enzyme that compensates for 
telomere shortening by adding telomeric repeats to chromosome termini (23, 24). This RNP 
uses its RNA component as a template for telomere repeat addition (25, 26). It is clear that 
telomerase is the primary enzyme responsible for telomere maintenance in humans, in the 
ciliate Tetrahymena thermophi/a, and in the yeasts Saccharomyces cerevisiae and 
Kluyveromyces lactis (27-32). However, alternative pathways for telomere replication do 
exist (33-36). 
Telomere length is dynamic in many organisms (e.g 31, 37-39). In humans, telomeres 
of somatic cells shorten with age both in vitro and in vivo (1,3). In addition, aberrant 
telomere shortening has been observed in aging-related genetic disorders such as Down's 
syndrome, ataxia telangiectasia and Hutchinson-Gilford progeria (40-43). It has been 
suggested that telomere length may regulate the aging process, perhaps by limiting a cell's 
proliferative capacity (1). However, age-related telomere shortening does not occur in well-
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studied models of senescence such as yeast and Paramecium (44, 45), and it has yet to be 
determined if telomere shortening is necessary for human aging. 
Human cells with a potentially unlimited proliferative capacity, such as germline cells 
or immortalized cancers, maintain their telomeres at viable lengths ( 46). In agreement with 
these observations, telomerase activity has been found in most immortalized cancers but not 
in most somatic cells ( 46). Also, antisense experiments have shown that an immortal cancer 
will stop growing if its telomerase activity is (47). Therefore, telomerase, presumably by 
regulating telomere length, plays a critical role in immortalization of cancer cells. 
What are anabolic-androgenic steroids? 
It has been reported that more than one million Americans are current or former users 
of anabolic-androgenic steroids (AAS) ( 48). Germans have used them first during the World 
War II to increase aggressiveness and strength of their army. The Russians first used them in 
athletics in 1954 ( 49). 
AAS are all derivatives, man-made versions of testosterone, the natural male-sex 
hormone (50). The Leydig cells, located in the testes, produce testosterone (discovered in 
1935) (51). There are 2.5 to 10 mg of testosterone produced by an adult male every day with 
the highest amount generated in the morning (52). Women's bodies also contain a small 
amount of testosterone, but in their case it is produced when androstenedione is converted to 
testosterone in almost all tissues. 
Testosterone is not stored in the body in big amounts; therefore its production is 
continuous. Testosterone causes both the androgenic or masculinizing and anabolic or 
tissue-building effect. The increased production of testosterone starts in puberty and 
continues to adulthood. When the production of testosterone in males increases during 
puberty, the androgenic effect causes an increase in length and diameter of the penis, 
boosting the sex drive and the appearance of facial, pubic, and axillary hair. In addition, the 
anabolic effect is responsible for an increase in height, muscle mass and strength, deeper 
voice along with decrease in body fat. These changes will occur without any exercise or 
physical training (51). Testosterone also has a growth promoting effect on bone (52). 
Testosterone is known to enhance maximal voluntary strength in a dose dependent manner 
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and therefore it may increase performance in power-lifting events. However it has not been 
proven to improve performance in endurance events. It is also not clear why sprinters or 
swimmers abuse testosterone, although the requirement for increased strenght could be a 
motivating factor. One reason might be that testosterone enhances their performance by 
decreasing reaction time at the start, because it controls neuromuscular transmission. 
Another motivating factor may be that while using testosterone the athletes experience 
shorter recovery time between workouts, which allows them to train harder and more often, 
and also it increases explosive power, which is crucial in sprints and short swimming races 
(54). 
0 
Figure 1: Structure of testosterone (from Taylor 1982) (53) 
Another group of steroids are corticosteroids, but they have an opposite effect on 
body. They promote catabolism or protein metabolism (tissue breakdown) and not 
anabolism (tissue protein building) (51). This class of steroids is not analyzed herein. 
The AAS have a number of physiological effects that are similar to those of 
testosterone. These steroids enhance skeletal muscle growth, and have androgenic effects 
that promote male sexual characteristic development (55). These steroids are synthesized in 
order to preserve and expand some of the effects testosterone has on the body and decrease 
some of the others (56). Increased muscle mass and strength is enhanced if steroid use is 
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accompanied by exercise ( 49). Steroids are also responsible for an increase in muscle protein 
synthesis and size of muscle fibers (57). 
Structure of anabolic-androgenic steroids: 
AAS have a basic four-ring carbon structure (56). Natural steroids differ in the 
number of carbon atoms attached to the number 17 carbon atom in the skeleton and also in 
the manner in which hydrogen (H), oxygen (0) and hydroxyl group (OH) are attached to the 
carbon atoms (58). Synthetic steroids differ from the natural ones by altering one or more 
positions of the carbon ring and by adding methyl, hydroxyl, alkyl, esters, or benzoyl groups 
at one or more of its sides (56). 
0 
Figure 2: Sites on testosterone molecule altered to create AAS (from Taylor 1982) 
The most basic difference between the natural and the synthetic AAS is in the 
manipulation of their chemical structure to increase the anabolic effect and decrease the 
androgenic effects of the natural steroids in the synthetic ones. Since it was desirable to 
extend the lifespan of steroids in the body, their structure had been changed many times. The 
intensive manipulation of the AAS structure resulted in many different types of drugs, all of 
which still resemble testosterone (58). However, none of the androgens display exclusively 
androgenic or anabolic characteristics and effects (59). 
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If testosterone is ingested, the liver breaks it down and inactivates it through various 
metabolic pathways, before it could have any effect on the body. Therefore steroids have to 
be chemically modified to have a desired effect on the body. The process oral steroids are 
subjected to is alkylation, which prevents rapid breakdown by the liver. IrYectible steroids 
undergo esterification, which makes them highly soluble in lipids; so they can be stored in 
body fat. They are absorbed through longer time, which makes their detection by drug 
testing easier (58). 
How do steroids work? : 
Virtually all steroids as well as testosterone are extremely lipid-soluble (52). Only 
one percent of the steroids inside of the body are free steroids, the rest are attached to a 
variety of plasma proteins. The free steroids are taken up by the cell's diffusion mechanism 
and bind directly to receptors (58). The binding of the hormone to the receptor causes the 
receptor to change its shape and to migrate from the cytoplasm into the nucleus, where it 
associates with specific response elements and turns up or down the expression of nearby 
genes. The stimulated hormone-receptor complex operates as a gene regulatory protein (52). 
Since the receptor is present in virtually all cell types, it enables the circulating hormone, 
somehow triggering cell-specific gene responses (60). The connection formed permits the 
steroid molecule to deliver a cellular message to the receptor site, effecting some metabolic 
changes within the cell. 
The primary change in metabolism of the cell is increased protein synthesis, 
decreased protein breakdown and nitrogen preservation, which leads to increased cell size 
and strength of skeletal muscle. After the steroid cell delivers its cellular command, it moves 
to another receptor cell, hence delivering its message over and over until it is converted into a 
different compound and excreted in urine. This process is called fleeting. This feature of 
AAS to be converted into other compounds by chemical reactions is particularly important in 
discussion of possible side effects (61). When a certain androgen binds to a receptor, it 
induces a chain reaction of events in the target tissue: first, it triggers the transcription of 
particular mRNA, and second it guides the synthesis of specific proteins involved in growth 
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and cell division control (52). If the body's receptors are already saturated with a particular 
steroid, there will be no more tissue-building result with continued use (58). 
Androgen and anabolic receptors are expressed in the myonuclei of the muscle fibers 
and in capillaries. Myonuclei that have receptors like those mentioned previously, are 
represented in greater amounts in the neck and shoulder muscles than in the limb muscles. 
The use of AAS generates a multiplication of androgen-receptor-containing myonuclei in the 
shoulder girdle muscles, but not on the vastus lateralis. This might be why there are regional 
differences of the anabolic androgenic steroids expression on muscle fibers and on body 
components (60). Training increases the attraction of receptors to anabolic steroids, because 
it enhances muscle size and also the number of receptors accessible for binding (58). The 
key factor here is the right nourishment for the developing muscle tissue, which means 
regular intake of proteins and complex carbohydrates to maximize the addition of mass and 
strength. In women, the receptors in the muscle tissue are not saturated with testosterone to 
begin with therefore they are able to see striking changes in a short period of time after 
taking AAS (58). 
It has been suggested that anabolic steroids also enhance size and strength through a 
different mechanism. The body produces increased levels of cortisol, a catabolic substance 
that causes muscle tissue breakdown, through intense training ( 61 ). That is where the 
anabolic steroids come to play, because they may have an anticatabolic effect, preventing the 
muscle tissue breakdown by displacing the cortisol molecule from its receptors. That is why 
the recovery time shortens and any possible injuries that could occur in heavy training, like 
microscopic muscle tears, heal faster (61). 
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Figure 3: Mechanism of steroid molecule binding to a receptor in muscle cell (from 
Taylor 1982) 
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Modes of anabolic-androgenic steroid use: 
AAS are taken orally as tablets or capsules, by injection into muscles (commonly in 
the buttocks), or as patches, gels or creams that are rubbed into skin (58). As mentioned 
earlier, AAS were chemically modified to prevent rapid breakdown by the liver leading to 
better overall utilization. 
Oral preparations: 
Oral steroids or sublingual anabolic steroid preparations typically have short half-
lives (amount of time during which the blood level of the drug is reduced to one-half of its 
initial blood concentration), usually on the order of several hours (61). Consequently, if the 
drug serves only as an anabolic agent, it must be taken three to four times a day to maintain 
an appropriate blood level. For example, if a specific drug with a half-life of two hours is 
taken at a 1 OOmg dose and it is totally absorbed attaining blood concentration of 10 mg, two 
hours later the concentration will only be 5 mg, and in another two hours it will decrease to 
2.5 mg and so on (56). 
Effectiveness of Oral Steroids: 
Oral steroids are popular supplements, because they are easy to obtain and use. With 
regard to muscle growth, there is a controversy whether steroids called androstenedione and 
androstenediol, both precursors to testosterone, increase concentration of free and total 
testosterone in plasma in young healthy men. Studies done by Leder et al. (2000) and 
Mahesh et al. (1962) showed that androstenedione and dehydroepiandrosterone (DHEA) 
increase plasma levels of testosterone (62, 63). However, these studies were performed on 
only two women, both of whom showed a substantial increase in testosterone levels. The 
small number of research subjects in this study leaves any conclusions drawn from it in 
question. 
In contrast, the far more comprehensive studies by King, Brown and colleagues (64-
69) showed that ingestion of oral androstenedione did not have any effects on testosterone 
concentrations in young healthy men. The levels of free or total testosterone did not change 
during the eight-week cycle of training and androstenedione supplementation in subjects 
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tested. This suggests that there may be a different response to androstenedione in men and 
women that may be due to different testosterone concentration in their bodies and also the 
mechanism involved. 
In another study, when sublingual cyclodextrine androstenediol was taken by young 
healthy men, an increase in free and total testosterone was observed (64). There was also a 
modest increase in free testosterone in older men (30-58) when they took androstenediol 
together with herbal supplements (65). Since androstenediol is converted to testosterone 
three times quicker than androstenedione, it may cause greater increase in testosterone 
concentration (65). Herbal supplements seem to have minimal effect on the level of 
testosterone in experimental subjects (66, 67). 
Dehydroepiandrosterone (DHEA) is another supplement that has been claimed to 
increase levels of testosterone in plasma. The most up to date study done by King et al. ( 69) 
showed that DHEA does not have an effect on testosterone levels in young healthy men, 
however it does increase concentration of testosterone in postmenopausal women as 
observed by Morales et al. (70). 
Taken together, these studies suggest that the over the counter testosterone boosters 
are marginally useful and only one of them (androstenediol) appears to have reproducible 
testosterone boosting effects. Clearly, additional studies of the type carried out by King and 
colleagues are necessary to sort out all the direct and pleotropic effects of the use of these 
supplements. 
Oral steroids are absorbed from the gastrointestinal tract (stomach) or small proximal 
bowel and must first pass through the liver before entering the blood stream so they could be 
distributed throughout the body (61). They must be structured to withstand the strong acidic 
environment in the stomach and the circulation of the liver without getting degraded and 
inactivated along the way. Oral steroids will bind to the anabolic-androgenic receptors in the 
skeletal muscle cells after passing through the liver promoting the enhancement of protein 
synthesis. 
Many oral anabolic steroids were modified by an addition of a side chain or group of 
molecules like methyl, ethyl, alkyl or benzoyl group at the alpha position of the number 17 
carbon atom through a process called alkylation in order to resist inactivation on the first pass 
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(56). These modifications are unusually harsh upon the liver (61). The oral anabolic steroids 
most commonly used among athletes are: Anavar (oxandrolone), Winstrol (stanozolol), 
Maxibolin (orabolin), Halotestin, Adroyd and Dianabol (methandrostenolone) (56). The 
generic names are included in the parentheses. 
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Figure 4: Examples of Oral AAS (from Thomas 1988) Note: not all of these are anabolic 
(King, personal communication). 
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Injectable preparations: 
There are two types of the injectable steroids, the oil and the water-based anabolic 
steroid preparations (56). 
Oil-based preparations: 
The most common injectable androgens are the oil-based preparations, which contain 
a mixture of sesame seed oil and alcohol (61). They have much longer half-lives than the 
oral and the water-based injectable steroids since the intramuscular injections can be 
intervaled over a week or two without reducing the steroid blood level (56). They are slowly 
absorbed into the blood stream from the injection site without going first through the liver. 
Because of that, the liver experiences a much lower concentration of the drug than with oral 
anabolics (61). Therefore most of the injectable AAS have little effect on liver function and 
are related less to liver disease. Also they have a higher potential to bind with the skeletal 
muscle receptors than steroids that are taken orally (56). A few oral C-17 alkylated steroids 
are available as injectable compounds, for example Winstrol (stanozolol) and Dianabol 
(methandrostenolone) and have the same hepatic profiles as their oral counterparts. 
Most injectable steroids go through a process called esterification to reduce a quick 
breakdown by the liver (61). There are some alterations to the ring structure at the 17-beta or 
the 19-position. The esterification of the 17-beta-hydroxyl group increases the solubility of 
the steroid in the oil carrier by lowering its polarity, causing a slow release of a steroid 
molecule into the blood stream (56). Since the de-esterification of testosterone esters 
happens quickly in plasma, it is the slow release of the anabolics from the muscle storage that 
explains their extensive period of action (54). 
The disadvantage of oil-based steroids is that they usually cause pain or discomfort at the 
place of inoculation (gluteal muscles). The advantage is that two or more oil-based steroids 
can be mixed together in one syringe. They are often used together with an oral anabolic 
when bodybuilders "stack" their steroids. 
The most common injectable steroid preparations used by athletes today are 
testosterone propionate, testosterone cypionate, nandrolone phenpropionate (Durabolin), 
nandrolone decanoate (Deca-Durabolin), methandriol propionate, and primabolin (56). 
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Water-based preparations: 
Only a few of the injectable steroids are water-based suspensions. They are shorter-
lasting; examples include the testosterone and the stanozolol suspensions ( 61 ). Water-based 
preparations have half-lives that are almost the same as the half-lives of the oral steroids, so 
they need to be injected almost every day. There is not nearly as much pain and discomfort 
associated with the injection compared to the oil-based drugs. The use of water-based 
steroids is increasing due to the fact that the sesame seed oil (part of oil-based AAS) is very 
caloric. The disadvantages are that they are more expensive, less produced and less available 
than the oil-based steroids. 
The water-based steroids can be mixed with other water-based steroids and also with 
water-based vitamin B-12. The molecular structure of the water-based AAS is in most cases 
identical to the chemical structure of the oil-based drugs. 
The most commonly used preparations of the water-based steroids are testosterone 
and methandriol (56). There are also enhanced forms of injectable testosterone available on 
the market collectively referred to as testosterone esters (61). 
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Testosterone enanthate 
Testosterone propionate 
Figure 5: Examples of Injectable AAS (from Thomas 1988) 
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The transdermal preparations: 
A transdennal preparation of testosterone saturated onto sticky film (the patch) is also 
available. Male athletes usually apply the patch to the scrotal skin to enhance absorption 
(52). One downfall is that the transdennal testosterone patch only delivers 5 mg of 
testosterone daily. Since some athletes might use up to 1 g of testosterone enanthate per 
week, they would have to use twenty patches per day to match the amount an individual 
could get by one intramuscular injection. The cost and the practical problems that are 
associated with the patch (patch removal) prevent athletes from misusing this kind of AAS 
(54). Dihydrotestosterone is one example of a transdennal preparation (71). 
Doses of AAS taken by abusers are usually up 100 times greater than doses used for 
treating medical conditions (55). The AAS should never be mixed together with corticoid 
steroids, because of their reverse effects (50). 
Anabolic-androgenic steroids use: 
AAS are taken in cycles (periods of use) that last between six to 14 weeks (72). 
Anabolic steroids are often taken in combination by " stacking", a process when an abuser 
mixes oral and/or injectable types of steroids (55). There are many stacking regimens, but 
the following are the most common: either taking two or more oral anabolic steroids at the 
same time, or throughout the day, or taking one or more oral steroids, with one or more oil-
based injectable steroids, or taking one or more oil-based agents with one or more water-
based agents. Another two regimens include using Human Chorionic Gonadotropin (HCG) 
or pituitary stimulating hormones with any of the regiment that were listed above. 
The usage of smaller doses may also have a few advantages; first one is to diminish 
potential side effects and second is to increase the effectiveness of the treatment. Also it 
could reduce the harmful effect on the liver. Another possible plus is that liver would be 
slower to step up its degradation to one specific drug, since it is encountering much lower 
concentrations of many different steroids. Therefore the regimen that includes smaller doses 
of different drugs would last longer and experience the wear-off effect much later (56). 
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Trying to prevent a development of tolerance to a specific AAS (plateauing), some 
athletes alternate their steroids, taking various drugs in an overlapping pattern, or they might 
finish taking one drug and begin taking another one (51). 
Another steroid use technique is called pyramiding, and it involves gradual increase 
and decrease of steroid doses reaching a peak amount at mid-cycle (55). Gradual increase 
could be in the number of drugs used at one time, the dose and frequency of one or more 
steroids (72). 
In addition, steroid users might take other drugs like diuretics (for fluid retention), 
antiestrogens (for "breast" development), HCG (for testicular atrophy) and anti-acne 
medications together with steroids to reverse their adverse effects (51). 
Medical uses of anabolic-androgenic steroids: 
Many people are most familiar with AAS being used by athletes to enhance their 
performance through increased muscle size and strength, and by noncompetitive weight 
trainers for improvement in physical appearance. Since AAS are very powerful hormones, 
they are also used in medicine for many different treatments (61). 
They are used in hypogonadal men (men with damaged or undescended testes) to 
compensate for testosterone deficiency. The steroids that are used to treat this disorder 
include long-acting parenteral (injectable) testosterone esters (testosterone enanthate or 
testosterone cypionate) and are managed at one to three week intervals to increase the level 
of testosterone in plasma (59). There are two different transdermal delivery systems and a 
gel that contains testosterone available in addition to the parenteral testosterone (Testoderm, 
Androderm and AndroGel) (73). This treatment helps developing and restoring male 
secondary sexual characteristics and sexual behavior. The only thing that cannot be fully 
restored by steroid therapy is the spermatogenesis in hypogonadal males. 
Catabolic or protein-depleting states such as chronic infections, extensive surgery or 
severe trauma, are treated with AAS like ethylestrenol or oxandrolone (59). 
Steroids are also helpful in treating certain adolescent diseases, some types of anemias, and a 
relatively rare form of edema ( 61 ). 
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AAS such as ethylestrenol, nandrolone decanoate, and oxymetholone are used for 
treatment of anemias that are not manageable by any other therapy like congenital bone 
marrow failure anemias and renal insufficiency anemias (59). Androgens are sometimes 
used in treating metastatic breast cancer when bones are involved (73). The steroids 
( dromostolone propionate, nandrolone decanoate, fluoxymesterone and testosterone) are used 
in large doses to treat advanced carcinoma in women. 
Also in treatment of hereditary angioedema, hyperlipidemia, osteoporosis, short 
stature and arthritis, or during chemotherapy, AAS are often used as medications to improve 
the overall health of the patients (58). These compounds are also used in treating men with 
male pattern baldness (56). 
Muscles mass and number of muscle fibers decrease with age, therefore many aging 
individuals seek steroid treatment. Exogenous testosterone, when used regularly, can reverse 
some of the changes associated with aging such as deposition and distribution of fat, and 
alterations in bone, muscle and lean body mass (73). 
There is a particular focus on the tissue building and anti-catabolic effects of AAS for 
treatment of burn victims, AIDS or HIV positive patients, or patients malnourished from 
disease or advanced age. 
Testosterone supplementation has been also widely tested as means of male 
contraception, but right now any athlete who would use androgens for contraception, would 
be disqualified if he had to undergo drug testing. Since endogenous testosterone production 
decreases with age, recent research is investigating the use of androgen replacement as a safe 
and effective anti-aging therapy for middle-aged men. AAS may be able to recover an age-
related decrease in sexual desire and arousal in many men, as well as have a positive effect 
toward lowering cholesterol when used in proper doses ( 61 ). 
Side effects, adverse reactions and potential health consequences of steroid abuse: 
There are over 70 side effects of steroid use ranging from acne to liver cancer. The 
liver, cardiovascular and reproductive systems are the ones that suffer the most from steroid 
abuse. Effects also include depression and aggressive behavior often called "roid rage" (74). 
Roid rage is a steroid-induced, "spontaneous, highly aggressive, out-of-control behavior 
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where police either were called or should have intervened" (51). It may take years for side 
effects like heart attacks or strokes to show up, and some may not even be recognized like 
stunted growth (74). 
Since an average adult male produces less than lOmg of testosterone per day, by 
taking supplemental steroids athletes raise their androgen blood level to many times the 
amount that would be normally produced. All these extra androgens affect the hormonal 
balance and the reproductive system of the body. Synthetic steroids usually imitate 
endogenous androgens (natural testosterone), therefore causing the body to decrease its own 
production of testosterone. It takes approximately the body three weeks to shut down its own 
production of androgens. This is an induced hypogonadal state that is associated with 
decreased serum testosterone levels, testicular atrophy, and impaired sperm production, 
resulting in temporary infertility. As discussed earlier, this became a primary focus of many 
studies in how to use AAS as male contraception. However, this is only a temporary state 
and it will be reversed as soon as the intake of steroids ends. 
Other adverse effects are mostly results of androgens being converted to different 
compounds inside the body. Testosterone may be transformed into a slightly modified 
derivative called dihydrotestosterone (DHT) by an enzymatic reaction catalyzed by 5-alpha-
reductase. That molecule is a steroid that may be responsible for the harmful effects, because 
it binds 5 to 10 times more effectively to the receptor than testosterone does. It is noteworthy 
that the metabolite product DHT has not been shown to be anabolic in muscles (King, 
personal communication). These effects happen because muscle cells are not the only cells 
in the human body with receptor sites for steroid molecules, and also because steroid 
molecules are capable of delivering more than one type of message to the receptor site. The 
type of message that is delivered depends on the link between the receptor site and its 
location. For example a steroid molecule that is linked to a receptor site in a hair follicle may 
deliver a message to stop growing, which would lead to a male pattern baldness. Another 
one could be linked to a site in the prostate gland and would deliver a message for the gland 
to enlarge, therefore causing prostatitis. The amount and degree of these adverse effects 
depend on the concentration of receptor sites for the steroid molecules in the specific area. 
So for this reason steroids with high conversion rate to DHT should be avoided, since they 
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seem to be responsible for these side effects. There is a prescription drug called Finasteride 
that can be taken to block the conversion of testosterone to DHT. 
The amount and the choice of steroids are also very important in appearance of 
possible side effects. It is known that high doses of highly androgenic steroids like 
testosterone esters are much more prone to cause problems than highly anabolic, less 
androgenic drugs like methenolone or oxandrolone. 
AAS can also be converted into estrogen hormones by process called aromatization, 
which causes feminization of the breast tissue known as gynecomastia. This can be 
prevented by the use of anti-estrogenic compounds, unfortunately once this problem 
develops, only surgery can reverse it (75). 
Also hormonal system disruption is caused by high amounts of AAS. It includes 
reduced sperm production, shrinking of testicles, impotence, male pattern baldness, prostate 
enlargement and irreversible breast enlargement (gynecomastia) in boys and men. For 
women, it involves decreased body fat and breast size, deepening of the voice, growth of 
excessive body hair, loss of scalp hair, menstrual irregularities, fetal damage, clitoral 
enlargement and sterility. 
Another possible adverse reaction can affect the musculoskeletal system, because 
steroids may prematurely stop the lengthening of bones among adolescents of both sexes, 
causing an early permanent termination of growth (55). Also connective tissue injuries can 
be caused by excessive use of anabolic steroids (75). 
Steroid use causes high blood pressure, heart attacks and strokes in the cardiovascular 
system, fatal cysts and cancer of the liver, kidney damage, jaundice, dyslipidemia with 
elevated low-density lipoprotein cholesterol and severely reduced high-density lipoprotein 
cholesterol, intracranial hypertension, water retention and acne or cysts on the skin (55). 
Since the liver processes AAS, it is most likely to show effects associated with them 
(58). C-17 alkylated oral steroids can withstand the liver degradation the first time they are 
passing through, therefore having harsh effects on the organ (75). AAS will cause elevated 
liver counts in the function test readings indicating liver stress (life-threatening toxicity), 
even if athletes take them only for a short period of time (61). These readings will go down 
to normal after oral steroids are discontinued. 
20 
The far more dangerous problems associated with AAS are hepatocellular carcinoma 
(liver cancer) and peliosis hepatis (blood-filled sacs within the liver). Cancer is particularly 
interesting in the context of this thesis because many cancer cells are immortal and have 
stable telomere lengths via activation of telomerase. However, most of the cases reporting 
liver problems have been connected with extremely sick older patients, that were treated with 
C-17 alpha alkylated oral steroids for years of continuous use, and many of these patients had 
a particular type of anemia linked to liver tumors even without anabolic steroid therapy. 
Most of the accounted liver problems may be related to 17 alpha-alkylated oral steroids, 
since there have been no cysts or tumors found in body-builders taking the 17 beta-esterified 
injectable steroids. They seem to have little or no effect on the liver function at all. 
Actually, some recent studies suggest that the effect of AAS on liver in healthy 
athletes may have been greatly exaggerated. Only one out of 53 current or past steroid 
abusers showed an abnormal liver test, after undergoing laboratory testing and none of the 
subjects showed any side effects that could be attributed to steroids like high blood pressure, 
edema or acne. One of the most dangerous and powerful anabolic steroid, oxymetholone 
(formerly known as Anadrol), was tested on HIV positive men and women in another study. 
They were given 1,000 mg of the drug per week, which is more than some of the body-
builders would administer, for longer period of time. The subjects have gained a lot of lean 
muscle mass without weightlifting, and they experienced no significant problems with liver 
function, water retention or virilization (75). In conclusion it can be said that only one to 
three percent of individuals consuming greater than therapeutic doses of 17 alpha-alkylated 
steroids will develop a liver tumor within two to eight years. The latency period can be more 
then 30 years long, so some of the users may not even know about them. They only come to 
medical attention when they rupture and cause hemorrhage. 
Another very important potential side effect is the possibility of heart attack and 
stroke (58). For the great amount of people that are currently taking anabolic steroids, the 
number reporting cardiovascular complications is very small. There have been myocardial 
infarctions with sudden death, arrhythmias and stroke observed in young body-builders, but 
no one is sure yet if they were caused by steroid use or by genetic predispositions. 
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AAS also have a direct effect on myocite, growth, metabolism and programmed cell 
death, which is consistent with our hypothesis (73). The only certain thing right now is that 
blood samples from oral AAS users often have high level of low-density lipoprotein (LDL) 
cholesterol and lower level of high-density lipoprotein (HDL). Harmful LDL cholesterol 
impedes the arteries around the heart and the HDL cholesterol helps removing fat deposits 
from vessels. Studies on animals showed changes in the heart muscle after using anabolic 
steroids, and they might be the factors contributing to development of cardiomyopathy in 
humans (58). 
There is a reasonable concern about the adverse effects of excessive steroid use on the 
prostate gland (75). When people take synthetic sex hormones, the brain sends a signal to 
reduce the production of sex hormones in order to keep the body in balance. Sperm 
production in men decreases and it may stop after time without the natural production of sex 
hormones. This will lead to testicle shrinkage even though the sexual interest may increase 
for some time (58). Men may be in higher risk for prostate cancer resulting from AAS abuse 
(51). 
By injecting steroids, HIV or AIDS, hepatitis Band C, and infective endocarditis (a 
potentially fatal inflammation of the inner lining of the heart) can be spread as well. 
Increased aggressive behavior, particularly when high doses of steroids are taken, depression, 
mood swings, fatigue, restlessness, loss of appetite, and reduced sex drive when drug abuse is 
stopped are another very important health consequences of the steroid use (55). 
The psychological effects of taking therapeutic dosages of AAS involve an increase 
in mental attentiveness, mood elevation, enhancement in memory and concentration, and 
decrease of fatigue sensations. It has been shown that testosterone effects both development 
and function of the nervous system. Testosterone as well as AAS causes an increase of 
norepinephrine (nature's version of adrenaline) levels in the brain (51). The physiologic 
effect of AAS might be the reason for changes in athletic performance (52). In conclusion, 
brain changes due to steroid use are similar to those caused by amphetamines and tricyclic 
antidepressants ( 51 ). 
Only a few research studies suggest that increased aggression, depression, mania, 
psychosis, delirium, paranoia, suicides, and homicides are common side effects of AAS. 
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Others have concluded that these phenomena are rare. There is probably only one percent of 
psychiatric disorders caused by anabolic steroid use. Even among those that have been 
affected, it is not clear if it was caused by steroids, other drugs, or preceding mental illness. 
No significant differences were found in the study that compared the anabolic steroid users 
and nonusers. However there is a possibility of a predisposition in certain individuals and 
steroid may be sufficient enough to push them over the edge and play a role in the irrational, 
violent behavior. Many experienced steroid users have found that AAS increase particular 
preexisting personality problems. So, angry and hostile users will become angrier and more 
hostile, while normal men will train more aggressively, but will not generally become 
violent. 
There also seems to be a direct correlation between dosage and occurrence of 
syndromes, when psychiatric problems arise in study subjects. No major psychiatric effects 
have been noticed where described mean weekly dosage was 318 mg; in heavier users it was 
620 mg (75). But when they exceeded 318 mg of steroids per week, 11 out of 25 subjects 
(44%) showed mood disorders (elevations and depressions) (51). Also 90% of the light and 
moderate dosage users have not experienced similar symptoms to those described above (75). 
The reason that a violent behavior may be associated with steroid use could also be explained 
by an intake of other drugs like marijuana or alcohol. Alcohol is widely associated with 
reduced inhibitions and violent and aggressive behavior. There might be an interaction 
between steroids and alcohol causing personality changes and violence (58). 
Steroid use can also lead to psychological dependence in some individuals. It is not 
known whether the dependence is due to chemical effect on the brain or to the positive 
feedback and attitudes toward someone's physique. This may be the most dangerous aspect 
of steroid use to those affected by it. The end of extended anabolic steroid use frequently 
leaves the user in a state of low endogenous testosterone levels. For people with low self-
esteem, losing some of the steroid gains can be psychologically upsetting. These individuals 
will not be capable to resist steroid use. In addition, since the goal of hardcore bodybuilders 
is not most favorable muscle size, but the maximal muscle size, dosages can turn out to be 
excessive. It might be true that some body builder's dependence on steroids is caused more 
by their mental health than by the addictive nature of substances (75). 
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Table 1: Side effects of AAS 
1. Increased acne and serious cysts on face and body 
2. Increased aggressiveness, nervous tension, psychotic states, paranoia, antisocial 
behavior 
3. Initial increase in sex drive, later decrease in sex drive, impotence 
4. Gynecomastia in men, decreased breast size in women 
5. Gastrointestinal and leg muscle cramps 
6. Headaches, high blood pressure and dizziness 
7. Pain while urinating (due to prostate enlargement), plus scrotal and testicular pain 
8. Loss of scalp hair 
9. Increased growth of body and facial hair 
10. Atrophy of male sex organs, low sperm production 
11. Enlarged clitoris in women, disruption of menstruation 
12. Deepening of voice 
13. Decreased body fat 
14. Increased appetite 
15. Stunted growth 
From Voy (1991) and Yesalis (1993) (76) 
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Experiments, studies and results 
As previously stated in the abstract, one objective is to test the hypothesis that AAS 
have an effect on cell division as well as on cell size increase. Hopefully, by connecting 
disparate pieces of available data, proper assessment of this hypothesis may come to light. 
From the introduction one can learn all the putative facts and information about AAS, 
however the many contradictions in the literature suggest that they cannot all be true. 
Perhaps the relationship between the disorders and use of steroids is not as obvious as it 
seems. The major focus of this part of the paper is to analyze the studies done on AAS, 
helping to address some of the questions stated in the abstract. 
Effects of AAS on muscle structure: 
The most noticeable things about a body builder are his/her muscles. It is known that 
AAS increases the size of a muscle cell, but the effects on the number of muscle fibers have 
not been discussed. 
Hartgens et al. (2001) explored the effects of AAS on human deltoid muscle fibers in 
male athletes, with references to the dose/response relationship (60). Thirty-five strength-
trained volunteers participated in this double-blind study. All the athetes had at least 3 years 
of strength training experience, were doing minimum of four workouts or eight hours per 
week, and were between 20 and 45 years old. Fifteen of these athletes took nandrolone 
decanoate or placebo for 8 weeks (200 mg/week, intramuscularly), another 12 athletes self-
administered various AAS during that time and the last seven were the control group (non-
users). The AAS that 12 of the athletes took were purchased either on the black market (the 
quality was not known) or through a prescription from a doctor. 
Since strength training causes hypertrophy of the muscle tissue, experienced athletes 
exhibited muscle fiber expansion in different muscles. Researches have hypothesized that 
after some time of strength training the hypertrophic effects in the muscle fibers will no 
longer happen, and that hyperplasia (an abnormal increase in the number of cells in an organ 
or a tissue with consequent enlargement) is the reason why there is a continuation of muscle 
growth after reaching the plateau. This suggests that AAS may as well cause cell division as 
increase in cell size. 
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Cross-sectional studies have shown that muscle fibers are larger in AAS users than in 
non-users. However, after eight weeks no significant alterations of any muscle fiber 
parameter could be observed for either the nandrolone decanoate or the placebo group. This 
finding raises the question of whether eight weeks was enough time for the effects of the 
AAS to show. Previous work suggests that time may have been sufficient (King, p.c ). 
However, the possibility exists that if the study was conducted over longer period of time 
subtle changes may have been observed. When the researchers compared the control and the 
AAS groups they have found major differences in the muscle fiber size. The control group 
went without any change, but the AAS group demonstrated an increase in mean of muscle 
fiber diameter by 12.6%, with the type I muscle fiber increasing by 10.8% and the type II 
muscle fiber increasing by 14.6%. 
It was observed in this study that strength training together with the administration of 
various AAS by stacking caused an enlargement of the deltoid muscle fibers in experienced 
strength-trained athletes. However, there were no effects observed in the athletes injected 
with 200 mg ofnandrolone decanoate per week (60). 
It still needs to be determined why there were differences between these two groups. 
The increase in size of the muscle fibers might be a result of yet unknown effects of two or 
more AAS that were taken simultaneously by stacking. No one recorded what substances the 
athletes took, and what quality they were. It could be assumed that substances bought on the 
black market had many different chemicals in them besides what was listed on the label. The 
time and number of AAS could have played major roles in this case as well. Since one of the 
groups took only one AAS during the eight-week period, the effects might be slower to 
show. 
A study done by Bhasin et al. (2001) showed the effect of testosterone on skeletal 
muscle (54). Since it is known that experimentally induced androgen deficiency is linked to 
fat free mass loss, the replacement of physiologic testosterone in healthy men with androgen 
deficiency should cause an increase in muscle protein synthesis and fat free mass. The 
researchers hypothesized that even in older men and in men infected with HIV with low 
testosterone levels there would be an increase in fat free mass by testosterone 
supplementation. Studies conducted before 1980s used small amounts of AAS, the same as 
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the amounts used for treating androgen deficient men, however athletes are known to abuse 
AAS by taking supraphysiological doses of steroids. That is why doses of AAS in this 
experiment were the same as the ones used by power athletes. They injected 100 mg of 
testosterone enanthate weekly for ten weeks into seven hypogonadal men after they have 
been withdrawn from androgens for 10-12 weeks. It was observed that physiologic androgen 
replacement in young healthy hypogonadal men is correlated with gain in fat free mass, 
muscle size and strength. The next experiment was conducted using supraphysiological 
doses of AAS on healthy men whose age ranged from 19-40 years. The men were randomly 
assigned into four groups: placebo + no exercise, placebo + exercise, testosterone + no 
exercise, testosterone + exercise. They were injected with 600 mg of testosterone enanthate 
or placebo per week, for 10 weeks. Men assigned into exercise groups were lifting weights 
3x a week. The results suggested that testosterone together with exercise created greater 
increase in fat free mass and muscle size than in any of the other groups, and also a greater 
gains in muscle strength than in any of the non-exercising groups. 
Surprisingly in older men testosterone did not increase muscle strength, but that 
might be due to different phenomena like their fitness level, which was very high or the fact 
that not all of them were hypogonadal. Maybe in older men with low testosterone levels it 
would be possible to observe an increase in muscle strength and physical function after 
treatment with AAS. 
In HIV-infected men, several drugs have been used to treat the wasting of muscles 
related to the disease. These included dronabinol, megesterol acetate (appetite stimulants), 
human growth hormone (HGH), insulin-like growth factor (IGF)-1, androgens, and 
thalidomide (modulator of immune response). Significant increases in lean muscle mass in 
HIV infected men was observed with HGH after six weeks, however it did not continue with 
longer treatment (12 weeks). It might be possible that the weight gain early in treatment was 
due to water retention. 
This study also showed that use of HGH has many side effects including edema, 
arthralgias, myaglias, and jaw pain. Another down fall is that the HGH therapy is more 
expensive than the testosterone replacement therapy (54). 
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In the Bhasin et al. study, there were five placebo-controlled studies administered on 
HIV-infected men using the testosterone replacement therapy to treat weight loss. Three of 
them showed an increase in lean muscle mass, but two did not. The results might have been 
affected by nonrandom pick of participants, because in those three studies men with low 
testosterone levels were specifically chosen to participate. 
In the next part of the study, the effects of testosterone replacement therapy were 
determined in HIV -infected men with low testosterone and weight loss. Sixty-one 
participants were divided randomly into four groups (placebo and no exercise, testosterone 
and no exercise, placebo and exercise and testosterone and exercise). The participants were 
given placebo or testosterone enanthate intramuscularly every week for 16 weeks and then 
exercised under supervision three times a week for the whole length of the study. At the end 
the results were as following, the group that was given a placebo did not change in muscle 
strength in any of the five exercises (leg press, leg curl, bench press, and in pull downs), 
however in the other three groups a major increase in muscle strength was observed. 
Therefore it was concluded that testosterone replacement therapy does increase maximal 
voluntary strength, lean body mass and weight gain in HIV-infected men with low 
testosterone levels. 
The results seen in a graph done for this particular study were somewhat puzzling. 
The group that was given placebo and exercised had greater change in strength in leg press 
exercise than any of the other groups. There was no explanation for that particular detail in 
the study, but the figure shows 40 pounds difference in strength. This brings into question 
the possibility that the effect was not totally due to testosterone replacement therapy but 
rather the change might be more associated with the supervised strength program the 
participants had been subjected to, or with some other aspects we are not familiar with at this 
time. 
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Effect of testosterone replacement therapy on leg 
press in HIV infected men with weight loss and low 
testosterone levels 
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Figure 6: Effect of testosterone replacement therapy on leg press in HIV infected men 
with weight loss and low testosterone levels 
It has been determined by several studies that testosterone promotes hypertrophy of 
muscles by increasing muscle protein synthesis. Since androgen receptors are saturated or 
down regulated in most tissues, it is possible that supraphysiologic doses of AAS cause 
muscle hypertrophy through androgen-receptor-independent system. This has not been fully 
tested yet, and more research is needed in this area. Bhasin suggests that the way 
testosterone effects particular athlete is also influenced by his/her genetic background, HOH 
secretion, nutrition, exercise, and other types of hormones like glucocorticoids, thyroid 
hormones and cytokines. Healthy women that used supraphysiologic doses of testosterone 
showed increased nitrogen retention and weight gain. However it is not known whether 
replacements of testosterone can cause muscle mass and muscle strength increase in older 
women with androgen deficiency. 
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From this study it can be concluded that healthy hypogonadal men that used 
testosterone replacement therapy observed an increase in fat-free mass, muscle size and 
strength, as well as eugonadal men that were subjected to supraphysiologic doses of 
testosterone. Whether these effects were due to the steroids alone or to other factors remains 
to be determined rigorously. 
Effects of AAS on LDLC and HDLC levels: 
It has been mentioned earlier that steroids might cause changes in levels of high-
density and low-density lipoprotein cholesterol. In one study, for example, Webb et al. 
(1984) used 14 adult males, 11 body builders and three power weight lifters to address these 
issues (77). The participants took 50 to 100 mg of methandrostenolone every day together 
with testosterone and nandrolone decanoate injections of 100 to 200 mg weekly. The 
research suggested that changes in HDLC and LDLC caused by use of steroids might lead to 
elevated risks of atherogenesis. The subjects were all highly active athletes studied while on 
and off AAS. 
Effects of AAS on mortality in mammals: 
Since studying the long-term effects of steroids on human mortality is very difficult, 
many researchers used animal models. Bronson et al. (1997) used the mouse model (78). 
Their goal was to find the effects of AAS on life span of male mice and reason they died. 
They exposed male laboratory mice to a combination of four AAS for a period of six months. 
The levels ( 5 and 20 times more than tisual amounts for mice) and kinds of the AAS 
(testosterone, two 17-alkylated steroids, and ester of testosterone) were made to be relative to 
what body builders usually take. The subjects were monitored for one year after they had 
stopped taking AAS. There were two kinds of data that were particularly interesting in this 
experiment: the age at death and the reason why they died. 
The mice were judged based on many criteria like exhibiting loss of body weight, 
pale eyes, hunched posture while resting, swollen abdomen due to kidney or liver tumors, or 
sunken sides, poor or postponed response to physical stimulus, badly coordinated (shaky) 
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locomotion, and difficult breathing. Those mice showing some of the signs listed above were 
killed and autopsy was performed. 
Results showed that by age of 20 months 52% of the mice treated with high steroid 
dosage died or had been killed, compared with 33% of mice in the low dosage group and 
12% of the control group. Only two animals (both were in the high dosage group) died 
before the cessation of the steroid treatment due to kidney failure, the result of 
glomerulonephropathy. Most of the mice that died before they were a year old, suffered 
from glomerulonephropathy, and most of the animals that died after one year of age suffered 
from hepatocytic carcinomas, liver and kidney tumors. 
Since this study was supposed to mimic the behavior of human athletes and body 
builders abusing AAS, it must be shown how closely this study is related to human 
conditions. The study suggests that the treatment mice were exposed to can be compared 
only to extreme steroid abusers for different reasons. First, mice were exposed to steroids for 
about one fifth of their life, and secondly they did not have any withdrawal periods, like 
human bodybuilders do. Many of the symptoms and conditions seen in mice are very 
common side effects found in human body builders abusing AAS. For example the liver 
damage, mostly hepatocytic carcinoma and peliosis hepatis have been common in human 
athletes taking AAS. So it can be cautiously assumed that the results observed in mice are 
correlated with those commonly seen in humans especially when referring to damage of 
liver. Therefore it is reasonable to conclude that pathological results are associated with 
AAS abuse and they might appear a long time after the termination of the steroid use. This 
study has illustrated the dramatic effect that steroids can have on mammalian longevity. 
Cardiac arrest in humans due to AAS: 
A study by Hausmann et al. (1998) points out to steroids having an effect on life span 
of a 23-year old body builder (48). The subject was known to use AAS together with other 
performance enhancing drugs. He died from a sudden cardiac arrest. He had taken 
unspecified quantity of AAS mixed with other drugs for about nine months. After the 
autopsy they found that the subject had cardiac hypertrophy (heart enlargement), peliosis 
hepatis, fibrinous clots in the lungs, liver and kidney, cerebral edema and many other 
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symptoms. Subject unne was analyzed and they have found mesterolone, 
methandrostenolone, testosterone, nandrolone and clenbuterol. Since the urine ratio of 
testosterone to epitestosterone was 64: 1, it was clearly shown the subject had abused 
exogenous testosterone. 
There are many case studies reporting the relationship between the AAS abuse and 
sudden cardiac death. In 1988, McNutt et al. reported first cardiac death related to steroid 
abuse. Another was documented in weight lifter that used testosterone and aspirin at the 
same time (79). In cell cultures and in experimental animals, steroids caused destruction of 
mitochondria and abnormal myofibrils, necrotic cells, collagen production increase and 
decrease in myocyte capillary supply when joined with exercise. In humans, in 21-year-old 
weight lifter that died of cardiac arrest, autopsy revealed some structural alteration of heart 
caused by AAS abuse. They thought that his cardiac arrest resulted from a lack of blood 
supply in his hypertrophic myocardium. AAS may also cause clots of red blood cells, 
platelets aggregation, decline of heart stimulus, increase in potassium, calcium and phosphate 
levels therefore elevating the risk of atrial and ventricular fibrillation, and finally increase of 
heart rate. 
The subject in this particular study might have had a predisposition to heart disease that AAS 
made worse. Therefore, a research should be conducted to see if cases of sudden cardiac 
arrest are related to genetic predisposition. Results of this study make a clear statement that 
AAS are not safe when used in large quantities and without supervision. 
A study done by Parssinen et al. (2000) focused on mortality and the reason of an 
early death among people that were suspected to abuse AAS for extended periods of time 
(80). The research compared the mortality of the Finnish top weight lifters with the 
population controls. They have used 62 male athletes that were active power lifters during 
1977 and 1982. 
Since high physical activity is typically related to high life expectancy, it points to the 
usage of anabolic steroids as the reason for deviation from this standard. Athletes are 
expected to have reduced risk of many diseases like diabetes mellitus, heart disease and 
hypertension when they get older. It is thought that top athletes not abusing AAS should 
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have at least the same if not higher life expectancy and lower risk of chronic diseases as the 
control population. 
Results showed that mortality after 12 years for power lifters abusing AAS for several 
years was four times higher than mortality of the population controls, 12. 9% and 3 .1 % 
respectively. Eight out of 62 power lifters and 34 out of 1094 controls died by 1993, making 
the risk of death higher for AAS abusers. The power lifters died of diseases that are 
commonly thought of as the side effect of AAS. Three of them committed suicide, three died 
of myocardial infarction and two suffered from hepatic coma and non-Hodgkin's lymphoma. 
The myocardial infarctions were caused by coronary heart disease, cardiomyopathy, 
dyslipidaemia, hypertension or diabetes mellitus, while the hepatic coma was due to cirrhosis 
of liver. The average age among the deceased power lifters was 43 years, ranging from 36 to 
53 years. Out of the 34 deaths among the control population (age range between 25 to 64 
years), 50% was due to cardiovascular diseases, 24% were accidents, and cancer and suicide 
were both 12% (80). 
The data strongly points to the AAS as the reason of death among the Finnish power 
lifters, because the toxicity of liver and severe effects on heart have been among many 
common side effects of drug abuse. Even though there is not any known connection between 
the non-Hodgkin's lymphoma and the use of anabolic steroids yet, HGH usage and 
hematological malignancies had already been linked together by some researchers. The 
incidence of cancer and cardiovascular deaths were about the same in both groups and only 
the suicide rate was higher among power lifters than in the control group. 
It would have been helpful to let people know the mean age of death of the population 
control group, so they could compare it to that of power lifters. Even though, the study states 
power lifters only died either as a result of disease or suicide, it does not seem to be enough 
to prove that it was due to AAS abuse, since the rate for cardiovascular disease and cancer 
was about the same in both groups with suicide present in both as well. It might have been 
due to uneven numbers of subjects between the two groups. 
Luke et al. (1990) has described another case report of sudden cardiac death in a 
young body builder (81). The subject was a 21-year-old healthy weight lifter that collapsed 
while bench pressing. For a few months prior to this incidence he had been parenterally 
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taking nandrolone decanoate and testosterone cypionate. The autopsy revealed cardiac and 
renal hypertrophy, with myocardial fibrosis and necrosis. An analysis of his urine revealed 
metabolites of nandrolone (19-nor-testosterone ). 
The subject's heart showed hypertrophy on the left side, massive regional fibrosis, 
and hypertrophy of the left and right ventricles. Examination also showed many microscopic 
centers of severe myocardial fiber necrosis in several parts of the heart, and bilateral renal 
hypertrophy. Surprisingly, other organs including liver, kidneys and spleen were normal. 
This might as well be a case either of a toxic or viral myocarditis, or the result of an 
effect of a particular steroid or a group of steroids the subject had been taking. It is still a 
mystery waiting to be solved to see what triggered the fast myocardial growth, which 
produced necrosis of myocardial fibers, by outgrowing the blood source of the fibers. 
A report by Kennedy et al. (1993) described a case of two previously healthy soccer 
players (18 and 24 years old) that suffered from fatal cardiac arrests while they were training 
(82). This was also the first case that involves the anabolic steroid called oxymesterone 
(hydroxymethyltestosterone ). 
The autopsy findings exposed that the 18-year-old athlete suffered from hypertrophic 
cardiomyopathy, while they found signs of myocarditis in the other subject. The urine 
analysis detected the AAS oxymesterone. 
Even though it has not been proven yet, there is a strong evidence suggesting that 
AAS were the cause of an increase in a heart size (which together with the features of 
hypertrophic cardiomyopathy would predispose the first subject to a sudden death), increase 
in the left ventricular mass and the sensitivity to circulating catecholamines (increasing 
predisposition to cardiac death) in the first athlete and cause of an arrhythmia in the second 
athlete. The second athlete was also known for his sudden rages, which could have been an 
indication of his steroid use. 
AAS caused an increase in total cholesterol, which makes the coronary artery respond 
to catecholamines in rodents as well as in humans. 
The first vascular complications as a result of AAS use were reported in three · 
patients, treated for hypoplastic anemia with fluoxymesterone or methenolone enanthate. 
These patients acquired thrombosis of the superior sagittal sinus. 
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Severe non-fatal myocardial infarction was originally described in 1988 and fatal 
myocardial infarction in 1990. McNutt described the non-fatal infarction happening to a 22-
year-old weight lifter who was taking AAS for a short period of time (six weeks) (79). 
Another non-fatal infarction has been reported in a 23-year-old body builder. A 22-year-old 
athlete, that had abused AAS for a long time, suffered from a first fatal infarction in 1990. In 
another case, a 21-year-old weight lifter died while he was exercising, and an autopsy 
revealed metabolites of nandrolone decanoate in his urine. A 28-year-old body builder died 
of myocardial infarction in Denmark not long ago. Two myopathy occurrences have been 
reported as well, one in a 32-year-old body builder with 16-year-old history of AAS abuse. 
He suffered from an occlusion of his right cerebral artery. The second one was reported in a 
41-year-old body builder (82). 
Another sudden cardiac death in a young amateur body builder was reported by 
Dickerman et al. (1995) (83). The young body builder was 20 years old, and had a history of 
using anabolic steroids. He died of a cardiopulmonary arrest, and the autopsy showed that he 
had a hypertrophy of heart and left ventricle (his heart weighed 515g, normal heart weights 
250g). He had no previous medical history of any kind, but he was known to just complete a 
3-month period of various AAS that he got in Mexico. The anabolic steroids he took 
included the following: Primobolan-Depot (methenolone-depot), Testosterona (veterinarian 
testosterone enanthate) and Laurabolan (veterinarian nandrolone laurate). He collapsed, and 
suffered from sudden cardiac death, accompanied by idiopathic bilateral pulmonary bleeding. 
Research shows an existence of androgen receptors on primates' cardiac atrial and 
ventricular cells. In rats, the sarcomere unit in the myocardium was dissolved completely by 
the action of AAS and myocardial intracellular edema, mitochondrial swelling, myofibrillar 
changes and cell necrosis had been observed in guinea pigs taking Dianabol 
(methandrostenolone ). In dogs, that took methandienone, the researchers observed an 
increase in heart weight, when they compared them to the controls. The animals were given 
steroids in dosage per kilogram of body weight, which is parallel to human body builders. 
Left ventricular wall and mass will get thicker just by dynamic weight training, but the 
function of the heart will not be affected by it. AAS are thought to affect the myocardial 
function as well as to increase the platelet aggregation causing clots (83). 
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Table 2: Sudden death and mortality in athletes 
Athlete Age Disease Outcome AAS Source 
Bodybuilder 38 Wilm's tumor Died of Methandrostenolone Prat et al. 1977 
kidney 
cancer 
Daniel Unknown Unknown Died in AAS Voy et al. 1991 
Baroudi, 1984 
Bodybuilder 
Bodybuilder 37 AIDS, hepatitis Unknown Shared needled in AAS Sklarek et al. 1984 
use 
Bodybuilder 37 Hepatocellular Recovery Oxymetholone for five Goldman. 1985 
adenoma years 
Bodybuilder 27 Colonic Recovery Methenolone Edis&Lewitt, 1985 
adenocarcinoma enanthate, oxandrolone 
for six months 
Bodybuilder 40 Prostate cancer Died AAS use for over 20 Roberts&Essenhigh. 
years 1986 
Dave Singh Unknown Unknown Died in AAS Voy et al. 1991 
Bodvbuilder 1987 
Birgit Unknown Unknown Died in AAS Voy et al. 1991 
Dressel, 1987 
Heptathlon 
Bodybuilder 27 Hepatocellular Died from AAS use for three Creagh et al. 1988 
Adenoma hemorrhage years 
Bodybuilder 34 Cerebrovascular Partial AAS use for four years Frankie et. Al 1988 
thrombosis recovery 
Bodybuilder 32 Cardiomyopathy, Partial Used AAS since 16, Mochizuki&Richter 
cerebrovascular recovery stopped four months 1988 
thrombosis (?) before second stroke 
Power lifter 22 Myocardial Recovered Injectable and oral McNutt et al. 1988 
infarction AAS for six weeks 
Bodybuilder 26 AIDS Unknown Shared needles in AAS Scott&Scott, 1989 
use 
Bodybuilder 21 Sudden cardiac Died Injections of Luke et al. 1990 
death nandrolone and 
testosterone esters 
Bodybuilder 28 Cerebrovascular Recovered AAS injections for Laroche, 1990 
and peripheral three years 
thromboses 
Power lifter 30 Bleeding Recovered Stanozolol, Winwood et al. 1990 
esophageal oxandrolone, 
varices methandrostenolone 
use for 18 months 
Powerlifter Unknown Suicide Died before AAS and other drug Parssinen et al. 1999 
1993 use 
Powerlifter Unknown Suicide Died before AAS and other drug Parssinen et al. 1999 
1993 use 
Powerlifter Unknown Suicide Died before AAS and other drugs Parssinen et al. 1999 
1993 
Power lifter Unknown Myocardial Died before AAS and other Parssinen et al. 1999 
infarction 1993 enhancement drugs 
Table 2. Continued 
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Athlete A2e Disease Outcome AAS Source 
Powerlifter Unknown Acute Died AAS usage Parssinen et al. 1999 
myocardial 
infarction 
Powerlifter Unknown Acute Died AAS abuse Parssinen et al. 1999 
myocardial 
infarction 
Power lifter Unknown Hepatic coma Died AAS abuse Parssinen et al. 1999 
Powerlifter Unknown Non-Hodgkin's Died AAS abuse Parssinen et. Al 
lymphoma 1999 
Bodybuilder 20 Sudden Died AAS abuse, Dickerman et al. 
cardiopulmonary primobolan depot, 1995 
arrest testosterona, 
laurabolan 
Bodybuilder 23 Acute cardiac Died AAS, performance- Hausmann et al. 
arrest enhancing drugs 1998 
Football 18 Cardiac arrest Died Oxymesterone Kennedy&Lawrence, 
player 1998 
Football 24 Cardiac arrest Died Oxymesterone Kennedy&Lawrence, 
olaver 1998 
College 22 Myocardial Died Long term AAS abuse Kennedy&Lawrence, 
athlete infarction 1998 
Bodybuilder 23 Myocardial Recovered AAS abuse Bowman et al. 
infarction 
Bodybuilder 28 Myocardial Died AAS abuse Kennedy&Lawrence, 
infarction 1998 
Bodybuilder 32 Occlusion of Unknown AAS abuse for 16 Kennedy&Lawrence, 
cerebral arterv vears 1998 
Bodybuilder 41 Unknown Died AAS abuse Kennedy&Lawrence, 
1998 
From Lin (1990), Voy (1991), Hausmann et al. (1998), Parssinen et al. (2000), Kennedy 
(1998) and Dickermann et al. (1995) 
The effects of AAS on overall health of humans: 
A cross-sectional study was conducted by Hartgens et al. (1996) to investigate the 
effect of steroids on body composition, muscle fiber, cardiovascular risk factors and liver 
enzymes ofbody builders (57). All 16 subjects (AAS group) had been taking AAS for a long 
time (3 years on average) prior to the experiment, and they had been studied three months 
after the cessation of the drug use. They had been compared to a control group (CO group) 
that consisted of 12 body builders that had never used AAS before. The AAS group had 
taken 25 different steroids within about three year period, but it was not feasible to figure out 
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the average and total doses, because they had been on stacking regiment. The two groups 
were comparable on bases of age, height, percentage fat, fat mass and training (10 hours a 
week), however there was a difference in body weight and lean body mass, which were both 
greater in the AAS group. Also the circumference of the thorax, waist, upper arm and thigh 
was greater in the AAS group when compared to the CO group. Since the biopsy of the 
muscle samples showed that the water content for both group was about the same (76%), it 
could be concluded there was .no water retention in muscles due to steroids in the AAS 
group. 
The results showed that the body weight was larger in AAS group, they had greater 
lean body mass, circumferences and the diameter of a type I muscle fiber (slow-twitch 
fibers). There seemed to be no long term effect of AAS on distribution of the fiber type in 
the longitudinal studies, but it is known that weight exercises cause a hypertrophy of the type 
II muscle fibers (the fast-twitch fibers), therefore that might mask the dominant effect of 
AAS on the type I muscle fibers. Since there were differences in body composition of the 
two groups, it can be speculated they are due to AAS, however there are other factors that 
should be accounted for like differences in previous training and diet habits or genetic 
predispositions of the subjects. Surprisingly there were no differences in fat mass, blood 
pressure, lipoprotein reports and liver enzymes between these two groups, which contradicts 
some of the other studies done, such as a study done by Webb et al. (1984) (77). 
Since the drugs that AAS group used were purchased on the black market, their 
quality was highly questionable. Analysis showed that pills and bottle tags were made up or 
presented with non-registered trademark or company names. The pill content was diluted, 
non-sterile, or contained substances that were not listed on the label, or was missing the 
substances that were on the label. 
Studies have shown the increase in strength and lean body mass due to AAS (maybe 
by blood volume increase, fluid retention, or increase of muscle mass), as well as no increase 
in fat percentages and fat mass. This particular study had found long-term effect of AAS on 
body composition after the termination of the use. It could be hypothesized, that by starting 
another cycle of AAS before the effects of the previous one are completely gone, could result 
in summation of the effects in gain of muscle mass. 
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AAS and apoptosis: 
I have speculated that increase in cell size may be related to apoptosis in some way. 
Articles regarding apoptosis, steroid usage and the relationship between them were 
discussed. 
A study done by Abu-Shakra et al. (1997) researched the effect of high doses of 
stanozolol on skeletal muscle cells (84). The cells displayed signs of apoptosis like cellular 
and cytoplasmic shrinkage, membrane blebbing, DNA fragmentation, nuclear condensation 
and condensation of chromatin. 
The counterpart of apoptosis is necrosis, or inactive form of cellular death. In 
mammals, toxic substances and oxidative stress cause apoptosis in neonatal muscle and 
myoblastic cells. However, when the differentiated skeletal muscle gets injured, it undergoes 
necrosis. The goal of the experiment was to find out if differentiated muscle cells with 
multiple nuclei originated from murine C2 myoblasts would respond to injury caused by 
steroids by apoptosis. Anabolic steroids (stanozolol, danazol) produce serious harm in 
differentiated C2 muscle cells as proven by previous experiments while glucocorticoids are 
proven to induce active cellular death in T cells and leukemic cells through steroid receptor-
depended mechanism. Some steroids cause apoptosis when withdrawn from the cells 
(prostate epithelial cells). Surprisingly, in this study it appeared that androgen receptor does 
not play a role in apoptosis caused by AAS. 
Muscle cells were exposed to stanozolol (50 micro Mor 100 micro M), observed for 
signs of apoptosis in the injured muscle, and then compared to a control, in which the muscle 
cells were exposed to calcium ionophore (known to cause necrosis). The higher the steroid 
concentration in the culture, the higher was the number of cells undergoing apoptosis. The 
DNA of the cells treated with stanozolol did not cleave into random fragments (DNA 
smearing), which would have indicated necrosis of the cells, but it was cleaved into 180 base 
pair fragments indicating cell apoptosis. No major drop in the total protein levels and 
cellular ATP levels also showed that cells treated with stanozolol underwent apoptosis 
instead of necrosis, since there was a drop in case of cells treated with ionophore. 
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It can be concluded that apoptosis happens in fused and differentiated murine skeletal 
muscle cells, when they are subjected to steroid treatment. Apoptosis was reported also in 
neonatal skeletal muscle cells in rats as well as in cultured myoblasts, when subjected to 
steroid induced injury. The outcome of the study is uniform with reports of myocardial 
toxicity in young body builders abusing AAS. Cells will undergo apoptosis once they reach 
the so called "commitment point". It means that cells that have been exposed to 10 micro M 
of stanozolol for an hour will go through apoptosis, even if the steroid doses are terminated. 
Apoptosis involves transcription and protein synthesis (both energy-dependent) (84). 
Another study done by Zaugg et al. (2001) determined whether AAS induce apoptosis 
in ventricular myocytes of rats in vitro (85). Cells have been exposed to stanozolol, 
testosterone enanthate and testosterone for 20 hours. Different amounts of AAS starting 
from 0.1, 1, 10, and ending at 100 µM of each have been used. 
Results showed that AAS induce apoptosis in rat ventricular myocytes in 
concentration dependent way. Since apoptosis plays a major role in sudden cardiac deaths, 
these results are very important in understanding the pathogenesis of the heart involved with 
AAS abuse. Apoptosis seems to be a key process in a shift from the cardiac hypertrophy to 
cardiac death. AAS are known to have toxic effects on myocardium comparable to signs of 
congestive heart failure. 
Esterified testosterone enanthate was found to be the most successful in inducing 
programmed cell death in ventricular myocytes in vitro. It was found that apoptosis of 
cardiac cells is also generated by long-chain fatty acids. The critical doses of steroids 
increasing apoptosis are 10 µM of stanozolol, and 1 µM of testosterone enanthate, which 
equal to supraphysiological dosages used by human body builders. 
The heart seems to be a target organ for AAS, since their receptors have been found 
in cardiomyocytes of monkeys and rats. Another important factor affecting apoptosis is free 
Ca2+. Augmented cytosolic Ca2+ has an effect on permeability of mitochondrial membrane; 
it generates the discharge of apoptogenic factors as well as holocytochrome c, apoptosis-
inducing factor and caspase-9 from injured mitochondria, which is a major consequence in 
the beginning of apoptosis. 
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Gender differences have been reported concermng the myocyte death in the 
myocardium infarctions. The research is suggesting that changes in pro- and anti-apoptotic 
oncoproteins may cause vulnerability to apoptotic signaling in the heart of males. It might be 
hard to compare the results obtained from in vitro experiments and the situations created by 
abuse of supraphysiologic amounts of AAS in vivo. All that can be said at this time is that 
AAS are linked to sudden cardiac arrests, heart failure, myocardial infarctions, ventricular 
remodeling and cardiomyopathy, and these are all associated with apoptosis (85). 
AAS and thrombosis: 
Alvarado et al. (2001) has reported two cases oflimb-threatening arterial thrombosis 
caused by the anabolic steroid danazol ( danocrine) (86). Danazol is used to attain both 
prothrombotic and antithrombotic effects in medicine. There is yet no convincing evidence 
that steroids cause thrombosis in humans, however there are couple cases that are suggesting 
it. AAS had been considered a cause of arterial thrombosis in young athletes. Steroids are 
known to elevate aggregation and levels of platelets and to cause changes in various 
coagulation proteins. 
The first subject was a 40-year-old woman that had been taking 400 mg of danazol 
for medical purposes twice a day for period of eight weeks among other medications before 
the start of her vascular symptoms. It is thought that danazol caused increase in her platelet 
levels and arterial thrombosis. The second subject, a 71-year-old male had been taking 
danazol (400 mg a day) for his low platelet count. It had been speculated that danazol caused 
an arterial thrombosis in his case as well. After the patients discontinued danazol, their 
thrombotic symptoms vanished. 
The effects of AAS on IGFBP levels: 
Karila et al. (1998) performed a study that would show the effects of growth hormone 
and AAS on levels of IGFBP-3 in body builders (87). Nine athletes known to be abusing 
AAS and/or HGH were compared to a control group that consisted of 16 wrestlers that were 
not AAS abusers. Five athletes took HGH alone or together with self-administered AAS. 
The degrees of IGFBP-3 serum are constant in standard settings. The concentration of both 
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IGFBP-3 and IGF-1 (insulin-like growth factor-1) had risen as early as two days after the 
beginning of HGH administration. However, when subjects combined HGH with AAS, in 
two weeks the concentration levels had dropped in both serums. When the drugs were 
discontinued the serum levels went back to normal after several days. 
It is interesting that nandrolone lowers the serum IGFBP-3 level, but does not effect 
IGF-1 concentration, while testosterone increases the serum IGF-1 levels, but does not affect 
concentration oflGFBP-3. 
The results showed that heavy steroid abuse lowered both the basal IGFBP-3 
concentration as well as the one caused by HGH. On the other hand the serum IGF-1 
concentrations was found to depend on diet and varied among subjects. 
AAS decrease hormone-binding protein concentrations, for example in thyroxin, 
cortisol, and so on. In the future, it may be possible to use the IGF-system as a HGH doping 
control, since the levels of IGF-1 and IGFBP-3 increase after HGH intake. It is important to 
keep in mind that combining HGH with AAS, and low calorie diet will bring different results 
in doping detection. 
AAS and cell proliferation: 
It is known that AAS increase cell size, but studies have been done to show that AAS 
also induce cell division and proliferation. An article written by Kasperk et al. (1988) shows 
that androgens cause a bone cell proliferation and differentiation in vitro (88). Various doses 
of dihydrotestosterone (DHT) in osteoblastic mouse cells, human osteoblast cells, human 
osteosarcoma cell cultures, and TE89 have been used and it was found out that DHT induced 
cell proliferation in all regardless of the concentration, but with maximum at 10"-9 M. 
Different AAS like testosterone (the major circulating androgen), fluoxymesterone (synthetic 
androgen) and methenolone (anabolic steroid) express mitogenic effects in mouse bone cells 
and increase synthesis of DNA. The DHT mitogenic effect on bone cells was hindered by 
hydroxyflutamine and cyproterone acetate (antiandrogens), because they all bind to the 
androgen receptor. 
It is known that androgens preserve bone mass, and hypogonadal patients often suffer 
from osteoporosis, and fractures. It has been demonstrated by many studies that AAS 
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increase bone mass and bone formation, hence it could be speculated that bone cells contain 
androgen receptors. The skeletal mass increase in subjects that have been treated with AAS 
might have been caused by androgens affecting the bone structure. It cannot be assumed 
anymore that testosterone gets converted to estrogens by the bone cells and then it effects the 
cells through estrogen receptors contained within them, since DHT and fluoxymesterone, 
which cannot be converted to estrogens, increased cell proliferation in mice. However there 
is a possibility that testosterone gets converted to DHT in bone cells before the cell 
proliferation takes place. Testosterone has shown to have lower binding ability to the 
androgen receptor when compared to DHT, however in process of cell proliferation they 
have exhibited equal results, giving the idea stated previously. 
The results show that human and murine osteoblastic cells contain androgen receptors 
and undergo proliferation and differentiation in response to androgen stimulation. 
Quality of OTC dietary supplements: 
There is always a question of quality of AAS used in numerous studies discussed in 
the paper. A study done by Green et al. 2001 can answer many questions in this regard. 
They have analyzed over the counter (OTC) dietary supplement to find out if the content on 
the label and in the bottle were in sync (89). They have purchased 12 brands of supplements 
containing eight steroids in random fashion. 
Dehydroepiandrosterone (DHEA) and androstenedione are two of the most popular 
OTC steroids. Many athletes had claimed over the year that they have tested positive for 
something that they did not take, and what was not indicated on the label of their 
supplements. Hence, there was an apprehension about how pure and safe many OTC 
substances are. When analyzing OTC steroids, the researchers have found many 
inconsistencies between the labeling and the actual content. They were focusing on three 
different areas, whether all the substances listed on the label where present and in the right 
amounts and also whether anything else was there that should not have been. 
There were many departures from what was on the label, for example there should 
have been 250 mg of 4-androstene-3, 17-dione (androstenedione) in brand 2, instead they 
have detected only 166 mg (range was 163-170 mg). In half of the examined brands, they 
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have found various differences even among the pills in single bottles; they varied by 10% to 
20%. 
Brands that were labeled to have only one component (brands 1-8) showed many 
discrepancies, because only one contained 90-110% of the amount of steroid listed on the 
label (category 1 ), other seven contained less than 90% of the steroid listed (category 2), they 
ranged from 45-85%. Brands 1 and 2 had another substances in them that were not recorded 
on the tag and one of them was testosterone (category 3). 
For the brands that were supposed to have two or more steroids, brand 9 and 10 were 
missing one of the ingredients labeled (category 4). None of the brands with multiple 
ingredients fell into the category 1. Brand 12 contained 88.5 mg of the diol steroid instead of 
50 mg that were listed on the bottle (category 5). Also it was labeled to have Tribulus 
terrestris, which was not found. 
The results show that labels of the over-the-counter supplements were off in 
indicating the amounts of steroids as well as substances in the bottles. The customers are in 
most cases receiving less than they expected, paid and asked for. One brand contained nearly 
a double amount of steroid that was listed on the label and that can cause some harmful 
effects to an athlete who takes it. One brand had a testosterone in it, which is a controlled 
substance, and athletes will test positive during drug testing. The results from this particular 
study indicate that it is not safe for athletes to use OTC steroids, because of a major 
mislabeling of the supplements. 
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Conclusion: 
Detrimental Effects of Steroid Use 
A rigorous genetic analysis of the effects of AASs on health is difficult due to the 
limited data available. However, it is possible to draw some limited conclusions from the 
reports that are included in this thesis. After an extensive review of the scientific literature 
related to this topic, several conclusions can be made. It has been stated that AAS are widely 
abused by athletes and they are also used in medicine for treatment purposes. The first 
question asked in the beginning of this thesis was whether AAS cause cell division or 
increase in cell size, which, in turn, might lead to premature cell (and individual) death in 
steroid users. Many sources indicated that AAS increase the size of a muscle cell. Some 
reports indicated that certain steroids also increase cell proliferation and cell division in 
mouse cell cultures as well as in human cell cultures. Therefore we can only tentatively 
conclude that steroids may increase cell division in certain cell types and even cause a shorter 
life span of an individual who used them for extended period of time. The many case studies 
of steroid users along with the very few well-controlled population studies support this 
conclusion. 
Interestingly, though the data are limited, they suggest that steroid use may 
exacerbate an individual's genetic predisposition to specific pathological conditions. It is 
possible that the case studies that describe premature death or serious illness in steroid users 
are a reflection of the normal statistics for such events in an average population. However, it 
is particularly noteworthy that in the one available study that was relatively carefully 
controlled, the average age of death was significantly lower for steroid users than for non-
steroid users. In this study (80) the group of 67 men in the experimental category died at an 
average age of 43 . Interestingly, the conditions of death were similar to those observed in 
the normal population category (about 1000 males). However, the striking reduction in life 
span suggests that the use of steroids may have severely exacerbated preexisting genetically 
influenced physiological conditions, thereby leading to premature organismal death. In other 
words, steroids may cause an individual to die earlier of the same or related disease that 
would have killed him or her had they not used steroids and lived substantially longer. This 
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data should motivate additional studies of this type and give pause to individuals considering 
the use of steroids for muscle development. 
The role of telomere dynamics on premature cell death in steroid users remains 
completely untested. In a subsequent section, I will describe experimental strategies that 
could be used to address this deficit. Until studies of this nature are complete, the answer to 
the original hypothesis will remain unknown. However, based on the data presented herein, 
the concept of a telomere/cell division/premature cell death mechanism being involved in 
early demise of steroid users remains provocative and should be explored. 
Many of the studies described in this thesis were carried out in vitro, due to the 
logistical and ethical limits imposed on researchers interested in studies of this nature on 
humans. The lack of human studies severely impacts the ability to draw firm conclusions. 
Nonetheless, in many studies done in vitro steroids caused apoptosis, cell proliferation, cell 
necrosis and other cellular phenomena that are indicative of a detrimental effect of steroids 
on normal cell behavior. Thus, these in vitro studies bolster the proposal I make in this thesis 
that additional studies on animal models and human subjects is warranted 
Although anecdotal in nature, the large number of case studies of steroid users also 
shows a trend toward early death with emphasis on heart disease and cancer as the causative 
agents. In the section entitled "Proposed Experimental Strategies", I outline some tests that 
could shed further light on this subject. 
As mentioned earlier, there are a number of reports of sudden death in young athletes 
abusing steroids. While striking and probably indicative of the general detrimental effects of 
steroid abuse, the number of studies is too small, and the studies themselves poorly 
controlled, to provide definitive evidence that AAS cause a cardiac arrest and other life 
threatening phenomena in young athletes. 
At this point I feel that the most robust hypothesis that can be made is that a genetic 
predisposition can be enhanced by the use of steroids and that steroids do have potentially 
detrimental effects on cells in culture. 
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Other Factors 
Steroids are banned substances and most of the athletes get them on the black market. 
As reported in one of the analysis studies, the substances that athletes buy are impure and 
unsafe. Most of them do not contain the right amounts or all of substances listed on the 
labels and others might have some extras. Body builders taking these may suffer from 
different side effects that cannot be definitely linked to a certain steroid, because of the 
unknown content of a bottle. Amounts and purity of AAS are crucial in a body builder's 
diet, since they are already taking supraphysiologic amounts of drugs. Another steroid 
present in the pills, or amounts that exceed by 150-180% the amount stated on the labels may 
be enough to push the delicate balance of one's body over the edge. Thus, the ambiguity 
with regard to what an individual is actually taking when on a steroid regimen could play a 
major role in the ultimate outcome of their actions. 
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Appendix A: Experimental Strategies to Test the Hypothesis 
In this section I briefly outline experimental strategies that would test the hypothesis 
that use of steroids may contribute to premature cell death via a telomere dynamics 
mechanism. There is a substantial background of information suggesting that telomere 
length is strongly correlated with cellular age (1-4). Thus, it is reasonable to consider 
telomeres to be good indicators of the cellular aging process. 
Strategy 1 - Cell Culture 
In the first strategy, human cells in culture will be used. While indirect, this approach 
mitigates the issues surrounding the use of animals or human subjects. We will use non-
transformed primary muscle cells isolated from donors using a minimally invasive aspiration 
technique. The cells must not be transformed because immortal cells do not suffer the same 
telomere degradation, as do mortal cell lines, due to activation of the telomerase or some 
other telomere repair pathway. The cells will be grown in culture in two populations - those 
receiving steroids and those receiving no steroids in their growth media. Cell proliferation 
will be assayed on a regular basis, and telomere length will be monitored using a standard 
telomere length evaluation method (e.g., PCR amplification of telomere sequences followed 
by gel electrophoresis). The degree of correlation between steroid administration and 
telomere shortening/cell death will be monitored. 
Strategy II - Animal Model 
In a second strategy, a mammalian telomere model will be used. Rodents are 
somewhat unusual in that they contain extraordinarily long telomeres that could confuse the 
study. Despite this anomaly many successful studies of the relationship between telomere 
length and the aging process have been carried out using mouse models (86). Therefore, I 
propose here to use mice as the basis for this study. A colony of 100 mice will be divided 
into experimental (50) and control (50) populations. The experimental population will be 
administered 20x the normal androgenic maintenance for mice of a nandrolone decanoate 
and other steroids used in bodybuilding. The control group will be administered a placebo 
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injection. At regular intervals, steroid levels will be evaluated from each group. Telomere 
length will be determined from various tissues obtained from sacrificed animals at specific 
time points in the study. A correlation, if any exists, will be drawn between the length of 
telomeres observed and the cellular age and lifespan of the individual subjects. In addition to 
telomere length, electrophoretic and cytological methods will be used to monitor the general 
health of cells in these animals since these markers can be indicative of the onset of 
apoptosis. Finally, animal body mass and fat/muscle ratios will be monitored to obtain data 
regarding the lean mass gain as a function of steroid use. 
In an interesting ancillary strategy suggested during the writing of this thesis (F. 
Jansen, personal communication) a group of animals that have been genetically selected for 
their predisposition to exercise will be studies in the manner described above. In this study it 
will be interesting to ascertain whether the addition of above-average muscle activity 
enhances the effects of steroid administration observed for normal mice. 
Strategy III - Human Subjects 
In this study we will directly address the issue of cellular aging in steroid users vs. 
non-steroid users. This study will be difficult for several reasons and will require 
authorization for the use of human subjects and acquisition of human tissues. However, with 
all appropriate measures taken we will establish 6 groups of subjects. 
Female chronic steroid users 
Female subjects administered steroids for the duration of the study 
Female non-steroid users (control group) 
Male chronic steroid users 
Male subjects administered steroids for the duration of the study 
Male non-steroid users (control group) 
All subjects will be matched by age, health and genetics (health hist-0ry and family 
health history) to the extent possible. The subjects will be either administered nothing 
(chronic users), a fixed steroid regimen (normals+ steroids) or a placebo regimen (controls). 
All subjects will carry out a fixed resistance training program during the course of the study. 
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At various time points in the study, tissue samples will be taken by minimally invasive 
biopsy of muscle in a non-essential region. Additional tissue sample will be obtained as 
necessary. A PCR-based telomere length evaluation method (TRAP assay) will be carried 
out to evaluate the average telomere length in the various groups before, during and after the 
study. These data will be used to evaluate the potential relationship between telomere loss 
and steroid induced hyperplasia (cell growth). 
Summary 
The results of the studies suggested above will provide the strongest evidence to date 
with respect any relationship between steroid use (coupled with resistance training) and 
cellular aging as assayed by telomere length analysis in males and female humans. It is 
important to note that these studies are based on assumptions about telomeres acting as 
reporters of cellular age. While these assumptions have strong support in previous studies, 
they are not absolute and, therefore, the results of the studies can only be considered as 
supportive or non-supportive, rather than definitive. 
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Appendix B: The list of AAS 
Trade Name Generic Name Type Description Manufacturer 
Adroyd Oxymetholone 0 tablets, used for Parke-Davis 
anemia 
Agoviron Methyltestosterone 0 
Agoviron inj Testosterone Propionate I 
Agoviron-depot Testosterone I 
Suspension 
Ambosex Estandron 
Amino glute ahimid Cytadren 
Anabel Dianabol, Methandriol aqueous and oil Alto 
solutions 
Anabolicum Dianabol 
Anabolicum Vister Anabolicum Vister, 0 
Quinbolone 
Anabolikum Dianabol 
Anabolin Dianabol Rafa 
Anabolin LA-100 Nandrolone Decanoate 
Anaboline Deca-Durabolin 
Anador Anadur I 
Anadrol Oxymetholone 0 tablets. Used for Syntex 
anemia 
Anadrol 50 Oxymetholone 0 
Anadroyd Oxymetholone 0 Parke-Davis 
Anadurin Anadur 
Anamidol Oxymesterone 0 
Anapolon · Anadrol ICI 
Anapolon 50 Oxymetholone 0 
Anasteron Anadrol 0 Syntex 
Anasteronal Oxymetholone 0 
Anasyth Stanozolol I 
Anatrophill Oxandrolone 0 
Anatrofin Stenobolone Acetate I 
Anavar Oxandrolone 0 tablets Searle 
Andriol Testosterone O+I 
Undecanoate 
Andoredan Dianabol 0 
Andre 100 Testosterone Enanthate I long acting, oil 
Andre LA Testosterone Cypionate I long acting, oil 
Andre pository Testosterone Enanthate I long acting, oil 
Andro-Cyp Testosterone Cypionate I long acting, oil 
Androderm Clll T Watson 
Androfort-Richt Testosterone Propionate I short acting, oil 
Androgel T Uni med 
Android Methyltestosterone 0 aqueous suspension, Brown 
pellets 
I 
Androl-50 tablets 0 
Androlan Testosterone Propionate I short acting, oil 
Androlan Aqueous Testosterone I 
Suspension 
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Trade Name Generic Name Type Description Manufacturer 
Androlin Testosterone I 
Suspension 
Androlone-0200 Deca-Durabolin 
Andronaq LA Testosterone Cypionate long acting, oil 
Andronaq-50 Testosterone 
Suspension 
Andronate Testosterone Cypionate I 
Androral Methyltestosterone 0 
Androtardyl Testosterone Enanthate I long acting, oil Schering-Sepps 
Androviron Mesterolone 
Androxon Andriol 0 
Androyd Methyltestosterone 0 
Andryl 200 Testosterone Enanthate I long acting, oil 
Antitriol Oxandrolone 0 
Ara Test Testosterone Propionate I short acting, oil 
Arcosterone Methyltestosterone 0 
Arderone 100/200 Testosterone Enanthate I long acting, oil 
Ardomon Clo mid 
Balnimax Oxymesterone 0 
BayTestone Testosterone Propionate I 
Biogonadyl H.C.G. 
Bionabol Dianabol 
Boldane Boldenone 0 
Boldebal Equipose 
Bolfortan Testosterone Nicotinate 
Brumegon H.C.G. 
C.G. H.C.G. 
Catan id in Cata pres 
Catapresan Catapres 
Cea don Nolvadex 
Cesbron Clenbuterol 
Cheque Drops Mibolerone 0 
Chor. Gonadtropin H.C.G. 
Choragon H.C.G. 
Chorex H.C.G. 
Chorigon H.C.G. 
Choriolutin H.C.G. 
Chorion-Plus H.C.G. 
Choron 10 H.C.G. 
Chorulon vet H.C.G. 
Chorvlon H.C.G. 
Clenasma Clenbuterol 
Clom Clomid 
Clomifene Clomid 
Clomipheni citras Clomid 
Clomipheni citrate Clomid 
Clomivid Clo mid 
Clonidin Catapres 
Clonidine Cata pres 
Clonisin Cata pres 
Clonistada Cata pres 
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Trade Name Generic Name Type Description Manufacturer 
Clonidine HCL Cata pres 
Clostilbegyt Clo mid 
Com bi press Catapres 
Cotrapasmina Clenbuterol 
Contrasmina Clenbuterol 
Corgonject H.C.G. 
C-ratioph Clomid 
Crioxifeno Nolvadex 
Cyclamen Danazol 0 
Cynomel Cytomel 
Cyronine Cytomel 
Cytomel Tabs Cytomel 
Danabol Methandrostenolone 0 
Danatrol Danazol 0 
Danocrine Danazol 0 capsules, treatment of Winthrop 
endometriosis 
Danobrin Danazol 0 
Danol Danazol 0 
Deca-Durabol Deca-Durabolin Pharmacia 
Deca-Durabolin Nandrolone Decanoate oil-based, long lasting Organon 
Defarol Nolvadex 
De latest Testosterone Enanthate long acting, oil 
Delatestryl Testosterone Enanthate oily solution, Squibb 
Delyestryl BTG 
Pharmaceuticals 
Dep Andro-100-200 Testosterone Cypionate long acting, oil 
Depo Testosterone Testosterone Cypionate oily solution, Upjohn 
Deposterone Sustanon 250 
Depotest Testosterone Cypionate long acting, oil 
Dep-test Testosterone Cypionate long acting, oil 
Dep-testosterone Testosterone Cypionate long acting, oil 
Dia lone Dianabol 
Dianabol Methandrostenolone O+I white, blue, russian, Ciba 
tablets 
Dignotamoxi Nolvadex 
Dixarit Catapres 
Dostalon Dimethazine Richer 
Drolban Masteron oily solution, for breast Lilly 
carcinoma 
D-test Testosterone Enanthate long acting, oil 
Dufine Clomid 
Durabolin Nandrolone oily solution, Organon 
Phenylpropionate 
Durandron Sustanon 250 
Duratamoxifen Duratamoxifen 
Duratest Testosterone Cypionate long acting, oil 
Dura-testosterone Testosterone Enanthate long acting, oil 
Du rathate-200 Testosterone Enanthate long acting, oil 
Dynasten Anadrol 
Dyneric Clomid 
Eferox L-Thyroxine 
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Ekluton H.C.G. 
Elpihormo Deca-Durabolin 
Eltroxin L-Thyroxine 
Emblon Nolvadex 
Enarmon-depot Testosterone Enanthate I long acting, oil Takeda 
Encephan Dianabol 0 
Enoltestovis Hexoxymestrolum I 
Equipoise Bolden one I veterinary 
Undecylenate 
Ermalon Mestanolone 0 Roussel 
Esiclene Formebolone I 
Estratest Methyltestosterone 0 
Euthroid Cytomel 
Euthyrox L-Thyroxine 
Eutirox L-Thyroxine 
Everone Testosterone Enanthate long acting, oil 
Extraboline Deca-Durabolin oil-based, long lasting 
Farmo Nolvadex 
Fertodur Cyclofenil 
Finajet Trenbolone Acetate 
Finaplix Trenbolone Acetate 
Follutein H.C.G. 
Fortabol Laurabolin 
Fortadex Laurabolin 
G. chor."Endo" H.C.G. 
Ganabol Equipose 
Genabol Norbolethone 0 Wyeth 
Gestyl H.C.G. 
Glosso-Sterandryl Methyltestosterone 0 
Glukor H.C.G. 
Gonadoplex H.C.G. 
Gonadotrafon LH H.C.G. 
Gonadotraphon H.C.G. 
Gonadotropyl H.C.G. 
Ganie H.C.G. 
Gravosan Clomid 
Halotestin Fluoxymesterone 0 tablets Upjohn 
HCG Lepori H.C.G. 
Histerone inj Testosterone 
Suspension 
Hormobin Methyltestosterone 0 
Hybolin Imp Testosterone Cypionate I long acting, oil 
Hubernol Formebolone I 
lndovar Clomid 
Jebolan Deca-Durabolin 
Jectatest-LA Testosterone Enanthate 
Jenoxifen Nolvadex 
Kabolin Nadrolone 
Kessar Nolvadex 
Klomifen Clomid 
Kyliformon Clomid 
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Ladogar Danazol 0 
Lanabolin Methandrostenolone 0 
Laurabolin V Laurabolin I Organon 
Ledertam Nolvadex 
Levo id L-Thyroxine 
Levoroxine L-Thyroxine 
Levothroid inj L-Thyroxine 
Levothyroxine L-Thyroxine 
Levoxine L-Thyroxine 
Levoxyl Cytomel 
Linomel Cytomel 
Liothyrone L-Thyroxine 
Lonavar Oxandrolone 0 
Longivo Methyltestosterone 0 
L-Thyroxin Hennin L-Thyroxine 
L-Thyroxin Sodium L-Thyroxine 
Malogen Testosterone 
Suspension 
Malogen Cyp Testosterone Cypionate long acting, oil 
Malogen L.A Testosterone Enanthate long acting, oil 
Malogex Testosterone aqueous, short acting 
Malotrone Testosterone 
Suspension 
Ma mom it Cytadren 
Mandofen Nolvadex 
Masterid Masteron 
Masteril Dromostanolone 
propionate 
Masteron Dromostanolone 
propionate 
Mastisol Masterol Shionogi 
Mastofen Nolvadex 
Maxibolin Orabolin, Ethylestrenol 0 elixir, tablets Organon 
Maxiolin Elixier Orabolin 
Mediatric Methyltestosterone 0 
Mesteron Methyltestosterone 0 
Mestoranum Mesterolone 0 
Metabolina Methandrostenolone 0 
Metaboline Methandrostenolone 0 a multi-ingredient 
preparation 
Metanabol Dianabol 0 
Metandiabol Dianabol 
Metandren Methyltestosterone 0 tablets, capsules Ciba 
Metastenol Methandrostenolone 0 
Methandrostenolonu Dianabol 
m 
Methosarb Calusterone 0 tablets, for breast Upjohn 
carcinoma 
Metormon Dromostanolone 
propionate 
Miotolon Furazabol 0 
Mirfat Catapres 
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Monores Clenbuterol 
Myagen Bolasterone 0 Upjohn 
Nandrobolic L.A Deca-Durabolin 
Nandrol. Dec Deca-Durabolin 
Nandrolone Dec Deca-Durabolin 
Naposim Dianabol 
Nastenon Oxymetholone 0 Cassenne 
Neo Durabolic Deca-Durabolin I 
Neoclym Cyclofenil 
Neogonadil Bruco H.C.G. 
Neo-Hombreol Testosterone Propionate 0 short acting, oil 
Neo-Tiroimade Cytomel 
Nerobol Dianabol 0 
Nidolin Triacana 
Nilevar Norethandrolone 0 tablets Searle 
Nivelar Novethandrolone Searle 
Noltam Nolvadex 
Nolvadex D Nolvadex 
Nolvadex Forte Nolvadex 
Noncarcinon Nolvadex 
Norandren Deca-Durabolin 
Nortestonate Nandrolone 0 Upjohn 
Nourytam Nolvadex 
Novegam Clenbuterol 
Nurezan Deca-Durabolin 
Omifin Clomid 
Ondogyne Cyclofenil 
Orabolin Ethylestrenol 0 Organon 
Oranabol Oxymesterone 0 Farmitalia 
Ora-Testryl tabs Halotestin 0 tablets 
Oralsterone Fluoxymesterone 0 
Oratestin Fluoxymesterone 0 
Orchisterone Methyltestosterone 0 
Oreton Methyl Methyltestosterone 0 tablets, capsules 
Oreton Propionate Testosterone Propionate 0 tablets, oily solution Schering A-G 
Orgabolin drop Orabolin 0 Organon 
Orimetene Cytadren 
Ovogest H.C.G. 
Ovo-Gonadon H.C.G. 
Oxandrine tablets 0 BTG 
Pharmaceutical 
Oxeprax Nolvadex 
Oxitonsa Anadrol 
Oxitosona Oxymetholone 0 
Pace Equipose 
Panteston Andriol 
Parabolan Trenbolone Acetate 
Paracefan Cata pres 
Pardroyd Oxymetholone 0 
Perandren Methyltestosterone 0 Ciba-Geigy 
Perbolin Methandrostenolone 0 
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Pergotime Clomid 
Permastril Masteron 
Pharmachim Clenbuterol 
Physex H.C.G. 
Physex Leo H.C.G. 
Pioner Clomid 
Plenastril Anadren 0 
Praedyn H.C.G. 
Preda Ion H.C.G. 
Pregnesin Pregnesis 
Pregnyl H.C.G. 
Primobolan Methenolone 0 Schering A-G 
Primobolan Acetate Methenolone Acetate 0 oil-based.short lasting, Schering A-G 
fast acting 
Primobolan Depot Methanolone Enanthate oil-based, long lasting Schering A-G 
Primobolan S. Methenolone Acetate 
Primogonyl H.C.G. 
Primonabol Methenolone Acetate I 
Primotest Methyltestosterone 0 Schering A-G 
Proasi HP Proasi HP 
Profasi H.C.G. 
Prolan vet H.C.G. 
Prolifen Clomid 
Pronabol Dianabol Isis 
Pronabol 5 Methandione 0 G&G 
Prontovent Prontovent 
Proviron Mesterolone 0 Schering A-G 
Psychobolan Dynabolan 
Rehibin Cyclofenil 
Restandol Andriol 0 
Retabolil Deca-Durabolin Richter 
Retabolin Deca-Durabolin 
Riboxifen Nolvadex 
Roboral Anadrol 
Rochoric H.C.G. 
Rodozol Cytadren 
Ro-Thyronine Cytomel 
Roxilon Mebolazine 0 Richter 
S.L.T L-Thyroxine 
Serofene Clomid 
Serophene Clomid 
Serpafar Clomid 
Sexovid Cyclofenil 
Sinesex Methandriol 0 
Spas mo Mucosolvan 
Spiropent Clenbuterol 
Spriopent mite Clenbuterol 
Stenediol Methandriol 0 Organ on 
Stenobolone Stenobolone Acetate I 
Stenolon Dianabol 
Sten ox Halotestin 
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Steranabol Depot Oxabolone Cypionate I Farmitalia 
Steranabol Ritardo Oxabolone Cypionate I Farmitalia 
Sterandryl Testosterone Enanthate I long acting, oil Roussel 
Sternabol Clostebol 
Sterobolin Deca-Durabolin 
Stromba Stanozolol O+I Withrop 
Strombaject Stanozolol I 
Sustanon 250 a mixture of testosterone I oil-based, long lasting 
esters 
Sybolin Equipose 
Synasteron Anadrol 0 
Synthroid L-Thyroxine 
T. cell pharm Nolvadex 
T. citrate Nolvadex 
T. dumex Nolvadex 
T. Farmitalia Nolvadex 
T. Fermenta Nolvadex 
T. Heumann Nolvadex 
T. Hexal Nolvadex 
T. Jenapharm Testosterone Propionate short acting, oil 
T. Lachema Nolvadex 
T. lingvalete Methyltestosterone 0 
T. Onkolan Nolvadex 
T. Pan Medica Nolvadex 
T. Pharbita Nolvadex 
T. propionicum Testosterone Propionate short acting, oil 
T. Ratiopharm Nolvadex 
T. Sopharma Nolvadex 
T. Streuli Testosterone Propionate short acting, oil 
T. Vitis Testosterone Propionate short acting, oil 
T. Wassermann Nolvadex 
T. Berea Supp Testosterone Propionate short acting, oil 
T. prop. Eifel fango Testosterone Propionate short acting, oil 
T. Prop. Disp Testosterone Propionate short acting, oil 
T3 Cytomel 
T4 tabl L-Thyroxine 0 
Tadex Nolvadex 
Tafoxen Nolvadex 
Tamax Nolvadex 
Tamaxin Nolvadex 
Tamcal Nolvadex 
Tamexin Nolvadex 
Tamifen Nolvadex 
Tamofen Nolvadex 
Tamofene Nolvadex 
Tamoplex Nolvadex 
Tamox Nolvadex 
TamoxAL Nolvadex 
Tamoxan Nolvadex 
Tamox-GRY Nolvadex 
Tamoxifen Nolvadex 
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Tamoxifen Ebene Nolvadex 
Tamoxifen Funk Nolvadex 
Tamoxifen Hexal Nolvadex 
Tamoxifen Lerderle Nolvadex 
Tamoxifen Leivas Nolvadex 
Tamoxifen medac Nolvadex 
Tamoxifen mp Nolvadex 
Tamoxifen NM Nolvadex 
Tamoxifeno Nolvadex 
Tamoxifeno Septa Nolvadex 
Tamoxifeno Tablets Nolvadex 0 
Hs 
Tamoxifenum Nolvadex 
Tamoxifenum gF Nolvadex 
Tamoxifenum pch Nolvadex 
Tamoxigenat Nolvadex 
Tamox-Puren Nolvadex 
Tamoxusta Nolvadex 
Taxus Nolvadex 
Teatrois Triacana 
Teenofen Nolvadex 
Tertroxin Cytomel 
Tesamone Nolvadex 
Teslac Testolactone O+I tablets, aq.susp for Squibb 
breast carcinoma 
Tesone LA Testosterone LA 
Test Aqueous Testosterone water-based, short 
Suspension lasting, fast acting 
Test Prolongatum Testosterone Cypionate long acting, oil 
Testa-C Testosterone Cypionate long acting, oil 
Testadiate-Depot Testosterone Cypionate long acting, oil 
Testanate No 1 Testosterone Enanthate long acting, oil 
Testate Testosterone Cypionate long acting, oil 
Testaval Testosterone Enanthate long acting, oil 
Testex Testosterone Propionate short acting, oil 
Testex Leo Testosterone Propionate short acting, oil 
Testex Leo Testosterone Cypionate long acting, oil 
Prolongatum 
Testin Methyltestosterone 0 
Testosterone Prop Testosterone Propionate I short acting, oil 
Testo-Enant Testosterone Enanthate I long acting, oil Geymonod 
Testogan Testosterone Propionate I short acting, oil 
Testoject-50 Testosterone Cypionate I long acting, oil 
Testoject-LA Testosterone Cypionate I long acting, oil 
Testolin Testosterone I 
Suspension 
Testomet Methyltestosterone 0 
Teston Methyltestosterone 0 
Testone LA Testosterone Enanthate I long acting, oil 
Testormon Methyltestosterone 0 
Testorona 200 Testosterone Enanthate I long acting, oil 
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Testorona 50 Testosterone Propionate I short acting, oil 
Testosteron Testosterone Propionate I short acting, oil 
Testosterone-depot Testosterone Enanthate I long acting, oil 
Testostroval-PA Testosterone Enanthate I long acting, oil 
Testoviron Methyltestosterone 0 Schering A-G 
Testoviron depot Testosterone Enanthate I oil-based, long lasting 
Testovis Methyltestosterone 0 
Testovis depo Testosterone Propionate I short acting, oil 
Testred Methyltestosterone 0 INC Pharmaceutical 
Testred Cyp Testosterone Cypionate I long acting, oil 
Testrin-PA Testosterone Enanthate I long acting, oil 
Theranabol Oxymesterone Theraplix 
Therobolin 
Thevier L-Thyroxine 
Thybon forte Cytomel 
Thyrax L-Thyroxine 
Thyrex L-Thyroxine 
Thyro 4 L-Thyroxine 
Thyro Hormone L-Thyroxine 
Thyrotardin L-Thyroxine 
Thyroxin L-Thyroxine 
Thyroxin-natrium L-Thyroxine 
Tiromel Cytomel 
Tironina Cytomel 
Tiroxino leo L-Thyroxine 
Ti-Tre Cytomel 
Transderm T Alza Corporation 
Tokormon Clomid 
Trijod. Sanabo Cytomel 
Trijodthyr. 50 Cytomel 
Trijodthyr. Leo Cytomel 
Trijodthyronin Cytomel 
Trinergic Dianabol 
Triolandren Testosterone Propionate I short acting, oil 
Troformone Methandriol 0 
Trophobolene I 
Turinabol. Depot Deca-Durabolin I Jenapharm 
Turnibol Dehydrochlormethyl- 0 Jenapharm 
testosterone 
Ultandren Halotestin 0 Ciba, Basel 
Undestor Andriol 
Vasoprome Oxandrolone 
Vebonol Equipose 
Ventipulmin Clenbuterol 
Ventolase Clenbuterol 
Virigen Andriol 
Virilon Methyltestosterone 0 
Virormone Testosterone Propionate I oil-based, short 
lasting, fast acting 
Virormone Oral Methyltestosterone 0 
Winobanin Danazol 0 
Trade Name 
Winstrol 
Winstrol Depot 
Wintrol V 
Zemide 
Zenalosyn 
Ziremilon 
Zitazonium 
Generic Name 
Stanozolol 
Stanozolol 
Stanozolol 
Nolvadex 
Oxymetholone 
Deca-Durabolin 
Nolvadex 
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Type 
O+I 
I 
O+I 
Description 
tablets 
water-based, short 
lasting, fast acting 
veterinary 
Manufacturer 
Winthrop 
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